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Studies on Graphene-based Nanomaterials 
for Biomedical Applications 
Je Min Yoo 
Department of Chemistry 
The Graduate School 
Seoul National University 
Due to many of its unprecedented physical, electrical and chemical 
properties, graphene has gained enormous attention of researchers since its first 
historical discovery in 2004. Technically, the term ‘graphene’ refers to a two-
dimensional single-atom-thick graphite film that once was deemed to plausibly 
replace indium tin oxide for transparent flexible displays. In addition to the film 
type graphene suitable for macroscopic applications, the noticeable features of 
other forms of graphene-based nanomaterials in solution have been recently 
revealed for applications in other branches of science including biology and 
nanomedicine. Along with the current research trends in these areas giving special 
attention to employing novel nanomaterials, we have performed some innovative 
studies to demonstrate the importance of graphene and its derivatives for versatile 
applications in these fields. This dissertation thus highlights the implications of 
graphene film and graphene-based nanomaterials for human health and the 




Chapter 1 is an introductory guide to graphene-based nanomaterials, 
which include their applications in biology and medical science, relevant 
preparation steps and some recent toxicity/biodegradation studies.  
Chapter 2 discusses the use of chemical vapor deposition graphene film 
for degradation of phenolic compounds in industrial wastewater. Phenol and its 
derivatives are considered to be the major threatening substances as they can be 
potentially mutagenic and carcinogenic. Although previous attempts have 
successfully destructed these compounds through ferrous ion-based advanced 
oxidation processes, they require complicated and costly procedures including 
environmentally harmful residual salt removal and pH adjustment. The chapter 
suggests the unprecedented role of the CVD graphene film in the generation of 
hydroxyl radicals – the active components in AOP for phenol destruction – from 
hydrogen peroxide through immediate electron transfer, and demonstrates the 
application of a recyclable CVD graphene film as an environment-friendly catalyst 
without the need of additional treatments. 
Chapter 3 highlights the therapeutic application of graphene quantum dots 
for Parkinson’s disease. The pathological hallmark of Parkinson’s disease is closely 
related to the aggregation of misfolded α-synuclein fibrils. By inhibiting the 
fibrillation of α-synuclein and inducing disaggregation of mature fibrils as well as 
blocking their transmission to neighboring neurons, GQDs prevent/rescue the death 
of dopaminergic neurons in the midbrain through the penetration across the blood-
brain barrier. The outcomes indicate GQDs’ potent therapeutic efficacy and are 
especially promising as the current clinical drugs focus merely on alleviating motor 




Finally, Chapter 4 discusses another therapeutic aspect of graphene 
quantum dots for neurodegenerative diseases, their effects on Niemann-Pick type C 
disease. This study provides new insights on graphene quantum dots’ ability to 
deplete intracellular cholesterol and restore compromised autophagic flux to treat 
lysosomal storage diseases.  
 
Keyword : Graphene, Graphene Quantum Dots, Biomedical Applications, 
Environmental Catalyst, Nanomedicine, Neurodegenerative Diseases 
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Introduction of Graphene-based Nanomaterials 
 
1.1. Applications in Biology and Medical Science 
Since its first serendipitous, yet historical discovery by British scientists in 
2004,
1
 graphene has attracted significant attention of researchers from all fields of 
science for exploiting many of its exceptional properties. One of the major research 
foci has been replacing indium tin oxide (ITO) with large-scale, high-quality 
chemical vapor deposition (CVD) graphene for macroscopic applications such as 
flexible thin films for transparent electrodes. Additional studies in the fields of 
electronics, physics, and materials science have also been extensively investigated.
2
 
Recently, given an increasing consensus on graphene’s environmentally-
friendly aspects, researchers have considered employing graphene in other 
branches of science such as biology and medicine. Above all, dispersed graphene-
based nanomaterials including graphene oxides (GOs), graphene quantum dots 
(GQDs), and reduced graphene oxides (rGOs) are more frequently employed for 
biomedical applications while the term graphene refers to a two-dimensional 
atomic film. GOs and GQDs are especially broadly utilized for biomedical 
applications due to their high dispersibility and low cytotoxicity.  
 
 
* The contents of this chapter are reproduced from: 1) Je Min Yoo†, Jin Hyoun Kang† and 
Byung Hee Hong
*.
 Chemical Society Reviews (2015) 44, 4835-4852. ©  The Royal Society 
of Chemistry and 2) Je Min Yoo, Do Won Hwang and Byung Hee Hong. (2018) Graphene-
Based Nanomaterials. In: Lee D. (eds) Radionanomedicine. Biological and Medical Physics, 





Figure 1-T1. Characteristic features of graphene-based nanomaterials.  
Figure 1-T1 briefly summarizes the major features of GOs, GQDs and rGOs. In 
general, GOs are synthesized through the Hummer’s method and GQDs can be 
obtained by thermo-oxidative cutting of carbon precursors including GOs. Notably, 
GOs and GQDs have various functional groups available for further modifications, 
which can be utilized for specialized purposes and further enhance their 
dispersibility.  
 
1.1.1. Sensing Applications 
In the beginning, researchers have primarily focused on utilizing the ability 
of GOs to quench fluorescence and the availability of their functional groups for 




successfully detected fluorophore-labeled DNA on/off the basal plane of GOs.
3
 
This work was followed by detecting other small molecules such as phosphate 
containing metabolites, protein kinases, trypsin and neurotransmitters with 
appropriate surface modulations.
4–7
 A recent report by Mei et al. illustrated that 




 in living cells by 
exploiting the difference in fluorescence quenching.
8
 Some researchers devoted 
special attention to unusual characteristics of stem cell growth and differentiation 





1.1.2. Therapeutic Applications 
Graphene-based nanomaterials are also known to exhibit high absorbance 
in the NIR region, which gave rise to novel approaches for NIR laser-triggered 
selective ablation of cancer cells.
11,12
 With appropriate modifications with targeting 
moieties, graphene-based nanomaterials can specifically target malignant tumor 
cells without damaging the healthy ones. Interestingly, graphene-based 
nanomaterials’ hydrophobic basal plane can be exploited for various synergistic 
therapies. Some groups attended to the fact that hydrophobic anti-cancer drugs and 
photodynamic agents could be easily loaded onto the basal plane of graphene-
based materials through – interactions. By combining the photothermal ablation 
with either chemotherapies or photodynamic therapies, therapeutic effects came to 
be higher.
13,14
 NIR-responsive hyperthermia was not only utilized for the direct 
ablation of cells, but also employed as an external cue for controlled drug/gene 








Figure 1-1. Graphene based in vivo targeting imaging agents. (a) In vivo fluorescence 
images of GQD–HA in mice after tail vein injection. (b) Fluorescence intensity from 
dissected organs. (c) and (d) Bright field image and in vivo fluorescence image after GQD 
injection. (e) Time-dependent tumor growth curves.  
 
1.1.3. Fluorescence Bio-imaging 
Numerous drug delivery strategies and direct photothermal ablation of 
tumor cells have been accompanied by various graphene-based platforms. 
Although many of these studies performed in situ imaging of drug delivery/therapy, 
most of these studies utilized coated inorganic quantum dots and other fluorescence 
molecules attached to graphene-based materials to visualize the phenomena. In 
2013, Nahain et al. presented two graphene-based anti-cancer drug delivery 
methods using rGOs and GQDs.
18,19
 In the case of the rGO–hyaluronic acid (HA) 
conjugate system (avg. size  200 nm), spiropyran was additionally attached as a 






should be noted that these authors repeated similar experiments without attaching 
additional fluorescent materials. Instead, they utilized the intrinsic fluorescence of 
GQDs with an average size of 20 nm to confirm efficient targeting of GQD–HA to 
the desired receptors.
19 
Successful delivery of the GQD–HA conjugate to 
overexpressed CD44 receptors was confirmed by obtaining fluorescence images 
from the tumor tissue through both in vitro and in vivo observations (Fig. 1-1). 
Anti-cancer treatment was subsequently administered by releasing doxorubicin 
under mildly acidic conditions, which was loaded onto the basal plane of GQDs. 
Although previously studied graphene-based therapy/imaging applications included 
other fluorescent molecules, researchers endeavor to exploit the luminescence of 
GQDs for in situ therapy monitoring. In 2014, Ge et al. incorporated a few nano-
meter scale GQDs in highly efficient photodynamic cancer therapy with 
simultaneous fluorescence imaging.
20
 In this study, the authors successfully 
synthesized GQDs with a broad absorption spectrum and strong deep-red emission 
peaking at 680 nm. Through both in vitro and in vivo experiments, the authors 
clearly demonstrated that GQDs can be considered promising PDT agents, with a 
superior singlet oxygen quantum yield, photo- and pH-stability and even 
simultaneous fluorescent imaging. 
While most researchers have focused on exploiting GQDs’ fluorescence 
for monitoring in situ drug delivery to confirm successful targeting, Zheng et al. 
demonstrated that GQDs can be utilized as universal fluorophores that could reveal 
some important biological functions (Fig. 1-2).
21
 In this study, specific labeling and 
dynamic tracking of insulin receptors were achieved through GQDs fluorescence of 
internalized and recycled insulin receptors in adipocytes. The authors tried to 





Figure 1-2. Dynamic tracking of protein of interest. (a) Confocal fluorescence images of 
insulin conjugated GQDs (green, left) or with antibodies against insulin receptor (IR) (red, 
middle). (b) and (c) Cellular distribution of insulin receptors after (b) 10 min or (c) 1 h 
incubation with insulin-GQDs. Scale bar = 10 mm.  
 
the insulin receptors, the authors found that the internalization and recycling of 
insulin receptors are oppositely regulated by two distinct proteins: (1) apelin, which 
improves the insulin sensitivity, and (2) TNF-, which enhances the insulin 
resistance. Although this study alone did not fundamentally change the therapeutic 
approaches to diabetes treatment, divulging in important cellular/subcellular 
functions revealed by using the GQDs fluorescence would be helpful for various 
future biomedical studies. 
 
1.2. Preparation of Graphene-based Nanomaterials 




biological applications due to the low cytotoxicity, large surface area and high 
dispersibility in various polar solvents. GOs are typically obtained through the 
Hummer’s method while GQDs are prepared by thermo-oxidatively cut GOs or 
other carbon precursors. These graphene derivatives show outstanding optical 
properties, which make them suitable for versatile applications including bio-
imaging. Simple modifications of GOs and GQDs make these graphene derivatives 
better prepared for specific biomedical applications.  
 
1.2.1. Enhancing the Stability under Physiological Conditions 
GOs can be dispersed in distilled water without much aggregation for 
several months, but are prone to aggregation in physiological solutions which 
commonly contain ionic salts. One of the strategies for enhancing stability under 
biological conditions is introducing biocompatible hydrophilic polymers and 
reducing the size of GOs. Although the synthesized GOs exhibit wide size 
distributions, the average size can be reduced by sonication. Many recent reports 
indicate that the sonication assisted modifications reduce the average size of GOs 
owing to the high sonication energy, and large GO particles can be broken down 
into much smaller ones, as small as 10 nm.
22
 Since small sized GOs show 
improved dispersion stability in polar solvents including physiological solution,
23
 
sub-500 nm GOs were commonly used in bio-imaging. For modification with 
hydrophilic polymers, polyethylene glycol (PEG) is one of the most preferably 
used polymers. Sun et al. grafted branched PEGs on GOs for enhancing the 
dispersion stability in biological buffers and further application as imaging 
agents.
22
 In that study, PEGs were bonded to GOs through the reaction with epoxy 




exceptional stability in phosphate buffered saline (PBS). Many studies used PEGs 
to achieve high stability even in solutions with high concentrations of salts (B10% 
NaCl).
24
 Other biocompatible hydrophilic polymers such as polyamido amine 
(PAMAM), dextran (DEX) and polyacrylic acid (PAA) also can be used as a 
stabilizer by covalent modification methods.
25–27 
 
1.2.2. Reduction of GOs 
rGOs have been considered for photothermal therapy and photoacoustic 
imaging agents due to their high absorption cross-section in the NIR region. GOs 




 or chemical reduction,
30 
but 
chemical reduction is considered the easiest way to obtain rGOs. In 2007, 
Stankovich et al. demonstrated that hydrazine can reduce GOs dispersed in water.
30
 
Ever since, hydrazine has been widely used to produce rGOs. However, owing to 
the toxicity of hydrazine and insolubility of rGOs, further surface modifications 
have also been performed afterwards. Contrary to GOs, covalent surface 
modifications cannot drastically change the properties of rGOs as only a negligible 
amount of carboxyl and epoxy groups are present. Instead, non-covalent 
approaches using the – interaction between the basal plane and aromatic 
molecules are used to modulate the surface properties of rGOs based on the strong 
van der Waals interaction. To obtain highly dispersible rGOs, PEGs terminated 




In recent years, various proteins are employed as a reducing agent and 
stabilizer of GOs for better biocompatibility and stability. Liu et al. demonstrated 






The resulting gelatin-rGO nanosheets were also internalized in cells without 
considerable cytotoxicity, and used as effective in vitro imaging agents. Sheng et al. 
demonstrated that bovine serum albumin (BSA) can reduce GOs and 
simultaneously behave as a surfactant, producing hydrophilic rGOs which can be 




1.3. Toxicity of Graphene-based Nanomaterials 
Although CNTs and graphene-based materials are some of the most 
widely studied nanoscale sp
2
 carbon allotropes with very similar chemical 
compositions, recent studies have observed entirely different levels of toxicities 
from these two classes of materials.
34,35
 Unlike CNTs, most studies have generally 
agreed on the negligible cytotoxicity of graphene-based materials. 
 
1.3.1. In vitro Toxicity of Graphene-based Nanomaterials 
Over the last few years, several groups investigated cellular 
internalization and in vitro cytotoxicity of functionalized graphene derivatives: 
GOs and GQDs using different types of mammalian cells. These reports generally 
confirmed low cytotoxicity and relatively high cellular uptake, which makes 
graphene-based materials suitable for various biomedical applications.
36-41 
Nevertheless, some researchers argued that the cytotoxicity of a few hundred 
nanometer or micro-meter sized GOs is much higher than that of GQDs, which 
should not be disregarded in biomedical applications.
37,38
 In particular, some 
studies indicated that GOs and GO-based nanoplatelets are related to severe 
cytotoxicity and lung diseases.
42,43




specific cytotoxicity of GOs by performing cytotoxicity screening of GOs on 
multiple different cell lines.
44
 In general, the cytotoxicity of graphene-based 
materials was found to be strongly related to the size of particles, which could 
partially explain lower cytotoxicity of a few nano-meter sized GQDs over a few 
micro-meter sized GOs.
38,43,45
 On the contrary, Akhavan et al., have repeatedly 
argued that the cytotoxicity of graphene-based materials is independent of size, but 
direct interaction of the sharp edges of graphene with the cell membranes is more 
likely a mechanism underlying the observed cytotoxicity.
46,47
 In other words, the 
authors believe that nano-sized GOs can also be lethal to mammalian cells. Thus, 
detailed toxicity mechanisms pertaining to the size and shape of graphene-based 
materials are still uncertain and further studies seem unavoidable. 
In addition, the effects of graphene functionalization in cell membrane 
permeability and cytotoxicity were studied by many researchers. The authors 
commonly discussed that covalently attaching hydrophilic molecules such as 
polyethylene glycol (PEG) to the edges of graphene enhances solubility and 
biocompatibility in a biological environment.
22
 Some authors investigated possible 
toxicity effects of the functional groups by modifying them with –COOH, NH2, 
CO–N(CH3)2, and –PEG.
41,48
 Quantitative data analysis showed no distinct toxicity 
changes among these GQD variants, while the cell membrane permeability 
increased respectively in the order of –PEG, –OH, and –NH2.
49
 These results are 
encouraging for researchers who endeavor to employ modified graphene 
derivatives as they all exhibit very low cytotoxicity.
50
 In 2011, Sasidharan et al. 
studied distinct behaviors between pristine/hydrophobic graphene and 
carboxylated/hydrophilic graphene in biological environments. Compared to 




cell membrane and the associated toxic effects such as the deformation of cell 
membrane and increased intracellular ROS level and subsequent apoptosis.
39
 
Indeed, graphene functionalization plays a vital role not only in cell-nanoparticle 
interactions, but also in enzyme-catalyzed biodegradation, which will be discussed 
in a later paragraph. 
 
1.3.2. In vivo Toxicity of Graphene-based Nanomaterials 
Besides the in vitro toxicity studies addressed above, many authors have 
explored in vivo bio-distribution and toxicology of graphene-based materials 
recently. In 2010, Yang et al. discussed the long-term in vivo pharmacokinetics and 
bio-distribution of PEGylated 
125
I-labeled nano-graphene sheets (NGS) with 
systemic toxicology examination.
51
 The radioactivity levels of 
125
I-NGS-PEG were 
measured in the blood and many different organs over time after intravenous 
injection. Overall, they found persistently decreased radioactivity levels of 
125
I-
NGS-PEG in most organs. They presumed that small NGS-PEG particles may be 
cleared out by renal or fecal excretion. The authors also investigated long-term in 
vivo toxicology over 3 months by carrying out blood biochemistry and hematology 
analysis. Mice injected with 20 mg/kg NGS-PEG were sacrificed at different 
periods of time, and all parameters from the blood biochemistry and hematological 
data did not indicate any appreciable toxicity. In 2013, the same group carried out 
in vivo bio-distribution and toxicology studies of functionalized nano-GOs by 
administering it through two other major routes: oral feeding and intraperitoneal 
(i.p.) injection.
36
 They revealed that oral administration induced no obvious tissue 
uptake, while i.p. injection led to high accumulation of nano-GOs in the RES 





Figure 1-3. In vivo imaging and bio-distribution of the carboxylated GQDs. (a) The in vivo 
imaging of KB tumor bearing mice after intravenous injection of GQDs (5 and 10 mg/kg). 
(b) and (c) ex vivo images and quantitative distribution of isolated organs of mice at 24 h 
after injection.  
 
injection, they found that both routes did not result in significant toxicity to the 
treated animals. 
In 2014, Nurunnabi et al. reported in vivo bio-distribution and toxicity of 
carboxylated GQDs by intravenously injecting them into mice.
52
 The accumulation 
and potential toxicity were tested by performing a long-term serum biochemical 
analysis and histological evaluations. Overall, the study revealed no serious in vivo 
toxicity and GQDs were mainly found in the liver, spleen, lung, kidney, and tumor 
sites (Fig. 1-3). Further study confirmed that GQDs did not yield any appreciable 




mg/kg or 10 mg/kg dosages for 21 days. These results were followed by similar 
conclusions of in vivo bio-distribution studies, illustrating fast clearance of GQDs 
from kidneys without significant accumulation in the main organs.
44
 Results of 
these biocompatibility studies suggest that GQDs can be used in clinical 
applications in the near future. However, these results also indicate that high doses 
of GOs can be toxic and have a lethal outcome, on good agreement with the results 
of in vitro studies. 
 
1.3.3. Biodegradation of Graphene-based Nanomaterials 
As much as various parameters of in vitro and in vivo toxicity studies are 
important, thorough understandings on oxidation–bio-degradation processes of 
graphene-based materials are crucial for universal and beneficial applications. In 
2011, Kotchey et al. reported enzyme-catalyzed oxidation of GOs and rGO by 
incubating each solution with low concentrations of hydrogen peroxide and 
horseradish peroxidase (HRP).
53
 Strikingly, the study revealed that the degree of 
functionalization is directly correlated with the degree of enzyme-catalyzed 
oxidation. Results from Raman spectroscopy, transmission electron microscopy 
(TEM) and atomic force microscopy (AFM) confirmed that mild enzymatic 
oxidation with HRP induced the formation of holey graphene oxide, which 
eventually resulted in fully oxidized debris of GO flakes (Fig. 1-4). On the other 
hand, incubation of rGOs with HRP did not make any significant changes in terms 
of enzymatic oxidation. The authors deduced that the presence of functional groups 
on GOs induced looser binding with HRP and allowed the enzyme to be more 
dynamic; the catalytic heme site of HRP was thus brought in proximity of GOs. On 





Figure 1-4. Enzymatic oxidation of GOs. (a) TEM images of GOs incubated with horse 
radish peroxidase (HRP). (b) AFM images with GOs incubated with HRP. (c) Simulated 
docking between GOs and HRP.  
 
making contacts with the catalytic heme site. In 2012, the same group reported 
thorough investigation on the enzyme-catalyzed degradation of CNMs using HRP 
and myeloperoxidase (MPO).
54 
The report verified promising aspects of 
functionalized CNMs for in vivo applications as they are presumably biodegradable 
by intracellular enzymes with peroxidase activity such as human MPO (hMPO). 
Nevertheless, it should be noted that the experimental results are not directly 
correlated with actual biodegradation in the human body as the physiological 
hMPO levels are generally more diluted than the experimental conditions. In 





1.4. Perspectives and Other Applications 
The promising aspects of graphene derivatives for biological and medical 
applications are: availability to produce various forms of graphene derivatives for 
different studies, high dispersibility upon conjugating diverse molecules and 
possibility to deliver drugs with specific targeting ability. The strong intrinsic 
Raman scattering signals can be utilized for Raman spectroscopy-based analysis, 
and increased NIR absorbance of the reduced version of derivatives is 
advantageous for successful relevant investigations. The fluorescence 
characteristics of GOs and GQDs can be tuned by modifying functional groups, 
and enhanced QY makes fluorescence bio-imaging another plausible method. 
Although CNTs exhibit some useful properties and have been considered for 
biological applications early on, the difficult separation steps may hinder large-
scale production of well-defined CNTs. On the other hand, the dispersed forms of 
graphene are more applicable to mass production. Solvo-thermal synthesis 
employing sodium had already achieved gram-scale graphene,
55
 and shear 
exfoliation in NMP can be readily used for industry-scale production.
56
 In addition, 
in contrast to the CNTs, graphene does not require further purification steps, which 
present a hurdle for CNT commercialization. The produced graphene can be further 
oxidized under oxidative conditions for introducing additional oxygenated 
functional groups, and functional ligands and biomolecules can be incorporated for 
increasing graphene’s water dispersibility and targeting, which is desired for 
biomedical applications. 
Among many graphene derivatives, CVD graphene exhibits high electron 




perfectly trap liquid for preventing vaporization under high vacuum or ultra-high 
vacuum conditions, which are the mandatory conditions for electron microscopy 
analysis. Thus, graphene can be utilized as an atomically thin window for in situ 
electron microscopy for liquid state samples, including various biomolecules and 
tissues. In addition, this single-atom thick film would make conformal contacts 
with non-conductive samples assuring the details of surface information. Thus, it 
could be employed as a novel conductive coating material for transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM) analysis where noble 
metals such as platinum (Pt) are currently used.  
In this chapter, recent biomedical applications, preparation and toxicity of 
graphene-based nanomaterials were reviewed. As mentioned, graphene has a 
number of exceptional properties for different biomedical studies including low 
toxicity and easily conjugatable functional groups. In addition, various forms of 
graphene also possess other remarkable properties including high Raman scattering 
intensity, large absorption cross section in the NIR region, and sharp photoacoustic 
contrast with the NIR incident beam. Based on the status of current research, it is 
expected that graphene-based nanomaterials will play vital roles in a number of 
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Catalytic Degradation of Phenols by 




Phenolic compounds are deemed as the major industrial pollutants as they are both 
mutagenic and carcinogenic. To destroy these substances, ferrous ion-based 
catalysts have been widely employed for oxidative destruction through advanced 
oxidation processes (AOPs). These agents, however, inevitably show several 
drawbacks including the need for pH adjustment and further purification steps to 
remove residual salts. Here we report the use of a chemical vapour deposition 
(CVD) graphene film as a novel metal-free catalyst for the AOP-based degradation 
of phenols in aqueous solution, which does not require additional steps for salt 
removal nor external energy to activate the process. We have also verified that the 
catalytic activity is strongly dependent on the surface area of the graphene film and 
the degradation efficiency can be markedly improved by exploiting an array of 
multiple graphene films. Finally, the recyclability of the graphene film has been 
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Phenol and its derivatives are important materials in many industries, but 
are also hazardous and potentially mutagenic and/or carcinogenic.
1–3
 For such 
reasons, destroying organic pollutants in an aquatic environment has been one of 
the major foci in the field of environmental medicine and wastewater treatment. To 
date, oxidative destruction of phenolic compounds has been carried out mostly 
through advanced oxidation processes (AOPs), which exploit the generated 
secondary radicals as powerful oxidants under aqueous conditions.
4–6
 To facilitate 
the processes while minimising disadvantages, a number of different catalysts 
including ferrous ion-based Fenton’s reagents have been widely employed. 
However, these agents necessitate further steps to remove residual salts and are 
optimised under relatively harsh conditions such as low pH. In addition, other 
candidates without ferrous ions predominantly demand external energies including 
UV light and electricity, which complicates their universal applications.
7–10
 
In this communication, we propose the application of a monolayer 
graphene film as a novel catalyst to degrade phenols through the AOP. Graphene 
has gained much attention in diverse fields of study due to many of its outstanding 
physical, chemical and electrical properties, as well as its exceptional ability to 
donate or withdraw electrons.
11–14
 We have thus inferred that a graphene film can 
be utilised to generate hydroxyl radicals from hydrogen peroxide (H2O2) through 
immediate redox reactions, where the generated radicals can be exploited to 





1.3. Results and Discussion 
 
Figure 2-1. (a) Schematic representation of the conventional phenol degradation method 
using Fe
2+
-based Fenton’s reagent (top) and the novel method with a recyclable graphene 
film (bottom). (b) Representative DCFH-DA fluorescence intensity (2 μM) with respect to 
increasing H2O2 concentrations in the presence of 1 cm
2
 Gr/SiO2 (blue), 1 cm
2
 SiO2 only 
(red), and non-treated (black). (c) Preliminary surface adsorption test of phenols (1 mM) in 
the presence (black) and absence (red) of 1 cm
2
 graphene film. (d) Representative DCFH-
DA fluorescence intensity (2 μM) in the presence of 1 cm
2
 Gr/PET (red line), Gr/SiO2 (blue 
line), PET only (red dot), SiO2 only (black dot), and non-treated (blue dot) and (e) mono- 
(red), bilayer Gr/SiO2 (black) and SiO2 only (blue) with the respective Raman spectra. (f) 
Time-dependent pH (black) and temperature (blue) changes in the presence of 1 cm
2
 




For the study, a high quality monolayer graphene film was synthesized 
through the chemical vapour deposition (CVD) method (Fig. 2-S1), and transferred 
onto a silicon substrate (Gr/SiO2).
15,16
 Ideally, graphene facilitates the AOP-
mediated destruction of phenols in an analogous manner to the conventional 
ferrous ion-based catalysts, but this would be more advantageous in multiple 
aspects: (i) further steps for salt removal would not be necessary, (ii) the optimal 
activity is not restricted to low pH, (iii) no input of external energy is required and 
(iv) the film is recyclable as long as graphene is not severely damaged and H2O2 
can be replenished (Fig. 2-1 a). 
To investigate the ability of the graphene film to generate hydroxyl 
radicals from H2O2, the fluorescence intensity of 2′,7′- dichlorofluorescin diacetate 
(DCFH-DA, 2 μM) was measured at different H2O2 concentrations. DCFH-DA is 
one of the most common fluorescent probes for the detection of reactive oxygen 
species (ROS),
17,18
 where its fluorescence intensity corresponds to the levels of 
ROS, Gr/SiO2 and bare SiO2, changes in the fluorescence intensity were monitored. 
While the non-treated and SiO2 only groups respectively resulted in a 12-fold and 
27-fold increase in the fluorescence intensity, Gr/SiO2 elicited a 102-fold increase 
with 100 mM H2O2 (Fig. 2-1 b). 
The difference in the fluorescence intensity solely arose from the presence 
of a 1 cm
2
 monolayer graphene sheet, which apparently took part in generating 
secondary radicals (i.e. hydroxyl radicals, OH·) from H2O2; the radicals’ strong 
oxidising potential is reflected by the dramatic fluorescence intensity increment. 
Indeed, previous reports including density functional theory (DFT) studies have 
explored the H2O2 reduction reaction (HPRR) on graphene, through which 






 More specifically, ambient H2O2 molecules are transiently adsorbed onto 
the surface of the graphene film mainly through the van der Waals force. Upon the 
spontaneous physisorption, breakage of the O–O bond is replaced by the formation 
of the C–O bond with graphene, where the adsorbed OH· on graphene plays the 
role of a strong oxidant against the surrounding targets like DCFH-DA.
21,22
 
Unlike the temporary adsorption of H2O2 molecules, the molecular 
adsorption of phenols on the graphene film may hinder their degradation process as 
these ring compounds are known to interact with graphene through hydrophobic 
interactions.
22
 On account of this potential issue, the adsorption of phenols on 
graphene was preliminarily tested by incubating 1 cm
2
 graphene in a 1 mM phenol 
solution (Fig. 2-1 c). As shown from the results, practically no phenol molecules 
were adsorbed onto the graphene films. It can thus be inferred that the – 
interactions between phenols and graphene are either only transient or negligible, 




To investigate the effects of the underlying substrate and the number of 
graphene sheets on the catalytic performance, monolayer graphene on flexible 
polyethylene terephthalate (PET) and bilayer graphene on SiO2 were prepared (Fig. 
2-1 d and e). As shown in Fig. 2-1 d, the substrate change resulted in only 
insignificant differences in the catalytic effect, as assessed by DCFH-DA 
fluorescence assay. Thus, Gr/SiO2 was exploited for all following assessments to 
facilitate relevant analyses including Raman and XPS. In like manner, mono- and 
bilayer graphene, which exhibited characteristic Raman 2D/G ratios of 4.27 and 
1.15, did not show critical changes in the catalytic effects (Fig. 2-1 e).
24
 The result 




graphene, which practically show no clear distinction.
25
 
In addition, the time-dependent pH and temperature changes were 
monitored by incubating 1 cm
2
 Gr/SiO2 and 1 mM phenols with 100 mM H2O2 
under ambient conditions (Fig. 2-1 f). Notably, the pH started at 6.06 and gradually 
increased with time, and saturated at 7.06 after 24 hours of incubation. The gradual 
pH increment can be attributed to the progressive consumption of phenols and 
H2O2, which are both weakly acidic, during the generation of hydroxyl radicals.
26,27
 
H2O2 is exploited for the production of hydroxyl radicals and phenols are degraded 
as a result of the process. Collectively, the final pH of this graphene-catalysed 
process reaches that of water, which is far more advantageous than ferrous ion-
based catalysts that are optimally activated in the pH range of 3–4.
5
 It should also 
be noted that there were no significant changes in the temperature during the 
course of phenol degradation except for the changes caused by the surrounding 
temperature. 
The effect of graphene-induced radicals on the degradation of phenols 
was subsequently investigated. Note that the concentration of H2O2 was adjusted to 
100 mM in all following assessments as the fluorescence intensity for the Gr/SiO2 
group was practically saturated from 100 mM onwards. After incubating 1 mM 
phenols with 1 cm
2
 Gr/SiO2 for 24 hours, the sample was analysed by time-
resolved ion-exchange high performance liquid chromatography (HPLC) (Fig. 2-2 
a). Besides the standard HPLC signal of phenol, which displays its characteristic 
peak at 68.56 minutes (Fig. 2-2 b), four other distinct signals were newly observed. 
To identify the substances designated by the emerged peaks, a HPLC-coupled 
organic acid analyser with a proton column and ultraviolet (UV) absorption 





Figure 2-2. (a) Time-resolved high-performance liquid chromatography (HPLC) analysis 
with the designated peaks representing the substances detected in the midst of the pathway. 
(b) Standard HPLC signals of phenol and maleic acid. (c) UV absorption spectra of the 
labelled intermediate compounds. (d) Schematic representation of the observed degradation 
pathway from phenol to maleic acid. 
 
substances separated at 16.65, 41.99, and 44.25 minutes post-injection, as they are 
likely to manifest less oxidised structures than the substance appearing at 9.74 
minutes (Fig. 2-2 c). Based on the reference UV spectra, we could verify that the 
obtained absorption spectra represent p-benzoquinone, hydroquinone, and catechol, 
respectively, for the HPLC signals at 16.65, 41.99, and 44.25 minutes.
28–30
 As 
expected, these compounds are the oxidative derivatives of phenol, with different 
degrees of oxidation. Although H2O2 signals peaking at 7.43 and 8.65 minutes 
overlapped with the peaks at 9.74 and 16.65 minutes (Fig. 2-S2 a), they did not 




The major substance appearing at 9.74 minutes post-injection was 
subsequently characterised with the HPLC-coupled organic acid analyser. 
According to the standard HPLC signals, the peak matches with that of maleic acid 
(Fig. 2-2 b), which features a biodegradable linear structure with four carbons. 
Previous studies discussing the potential pathway for oxidative destruction of 
phenol also report maleic acid as a dominant product through the complete 
oxidation of phenol to carbon dioxide and water.
4
 The report also classifies p-
benzoquinone, hydroquinone, and catechol as the major intermediate products prior 
to the ring opening process to maleic acid, while these substances are not deemed 
to be biodegradable yet (Fig. 2-2 d). 
 As 1 cm
2
 Gr/SiO2 could only elicit 25% reduction of the initial 
concentration of phenols (1 mM), we sought to improve the catalytic efficiency by 
exploiting an array of multiple graphene films (Fig. 2-3 a). Preliminarily, the 
relative DCFH-DA fluorescence intensity for graphene films with different areas –
1, 2, 4, and 9 cm
2
 – was measured to validate that the amount of generated radicals 
increases with respect to the area of the graphene film. Intriguingly, the 
fluorescence intensity markedly increased as a function of graphene area by 
exhibiting a 131, 208, and 913-fold increase in the fluorescence intensity 
respectively with 2, 4, and 9 cm
2 
Gr/SiO2 (Fig. 2-3 b). 
The same test groups were subsequently employed in time-dependent 
phenol degradation analysis with HPLC. In accordance with the results from 
DCFH-DA measurements, the oxidative destruction of phenols occurs in a time-
dependent manner with a strong dependency on the area of the graphene film. After 





Figure 2-3. (a) Schematic representation of multiple 1 cm
2
 graphene arrays to improve the 
catalytic performance. (b) Representative graphene area-dependent DCFH-DA fluorescence 
intensity (2 μM) with 100 mM H2O2. (c) Time-dependent changes in phenols and (d) 
maleic acid using graphene films with different unit areas. (e) Time-dependent changes in 
the amount of phenols through HPLC analysis of the recycled 9 cm
2
 graphene films with 
normalised phenolic levels. (f) Representative optical microscopy (OM) images and Raman 
spectra after performing the first, second, third and fifth incubation cycles. 
 
60%, and 92% respectively with 2, 4, and 9 cm
2
 Gr/SiO2 (Fig. 2-3 c). 
It should also be noted that the total amount of non-biodegradable ring 




Likewise, time-dependent maleic acid concentrations were monitored by using the 
HPLC-coupled organic acid analyser (Fig. 2-3 d). Interestingly for 9 cm
2
 Gr/SiO2, 
which exhibited the highest phenol reduction ratio, the concentration of maleic acid 
sharply increased after 3 hours of incubation. However, it shows a slight decline 
after 6 hours and becomes saturated until the end of the incubation period. Such 
inconsistent trends between the maleic acid increments and the phenol decrements 
can be attributed to the complete oxidation of maleic acid to carbon dioxide and 
water, which was supported by the generation of bubbles in the test batches. 
Finally, the recyclability of the graphene film was investigated by 
carrying out repetitive phenol destruction tests using a single 9 cm
2
 Gr/SiO2 sample 
(Fig. 2-3 e). After each cycle, the levels of phenols and oxidised intermediates were 
analysed. Remarkably, graphene films elicited the same catalytic effects after a 
series of recycling processes; four distinct time-resolved HPLC spectra for phenol 
degradation by the first, second, third, and fifth recycled 9 cm
2
 Gr/SiO2 display 
practically the same results (Fig. 2-3 e). On average, the concentration of the 
remaining phenol was 6.5 ± 2.3% in each tested cycle. This is nearly equivalent to 
the 92% reduction achieved with pristine 9 cm
2
 Gr/SiO2. 
For the analysis of the intrinsic properties of graphene, any damage or 
changes on the surface were evaluated through optical microscopy (OM), Raman 
spectroscopy and X-ray photoelectron spectroscopy (XPS) analyses (Fig. 2-3 f and 
Fig. 2-S3). The representative OM images clearly display that the graphene film 
was not damaged even after the fifth round of incubation cycle, and only a minimal 
part of stained spots were observed. The respective Raman spectra also supported 
that the original condition and quality of graphene were preserved over the fifth 




4.30, and 3.84 for the graphene film respectively after the first, second, third, and 
fifth recycling (2D peak at 2680 cm
−1
 and G peak at 1580 cm
−1
). In general, the 
2D/G ratio that exceeds 2 represents monolayer graphene, and a high 2D/G ratio 
typically corresponds to high intrinsic crystallinity. In addition, XPS analyses on 
the chemical composition of graphene pre- and post-phenol degradation exhibited 
essentially the same results, which corroborated that graphene was not severely 
oxidized by the surrounding hydrogen peroxide or organic molecules (Fig. 2-S3). 
 
1.4. Conclusion 
 In summary, we have successfully demonstrated the potential application 
of a CVD graphene film for the oxidative destruction of phenols through a novel 
AOP method. Although the catalytic activity of the graphene film-based AOP 
system is relatively lower and thus requires a longer incubation time than the 
conventional metal-based catalysts, it overcomes the inevitable drawbacks of the 
previous methods including the need for pH adjustment, input of external energies, 
and further steps for residual salt removal. In addition, it is important to note that 
the graphene film’s catalytic efficiency is markedly improved by enlarging the 
dimension of the film – which can be as large as 30 inches, produced by the roll-to-
roll method – which is expected to be utilized as a recyclable catalyst with 
considerable catalytic effects for industrial applications. As graphene can also be 
transferred onto flexible substrates, the range of potential applications can be even 
more broadened to different areas that demand the use of powerful secondary 





1.5. Experimental  
Preparation of CVD Graphene Film. Graphene was synthesised by the chemical 
vapour deposition (CVD) method on a highly pure copper foil (Alfa Aesar, 
99.95 %) according to the previous work.
13
 The growth was performed with 
flowing 40 sccm H2 and 5 sccm CH4 gas at 1000 
o
C. After coating a poly methyl 
methacrylate (PMMA) layer on a single side of as-grown graphene on Cu foil, the 
uncoated graphene was removed by oxygen plasma. The Cu foil was subsequently 
etched in ammonium persulfate (APS) solution (20 g/L) for 5 hours. The 
PMMA/Gr layer was then transferred onto SiO2 substrate, followed by baking at 80 
o
C for 24 hours to improve the adhesion. Finally, the PMMA layer was removed by 
acetone. 
Characterisation. Optical microscopy (OM) images were captured by a NIKON 
ECLIPSE LV 100 ND OM installed with NIS Elements D 4.20.00 software. A 
RENISHAW Raman spectrometer was used to characterise the quality and 
uniformity of the prepared graphene films. The Raman spectra were obtained using 
an Ar laser (514 nm) with a spot size of 1 mm. The samples were analysed by high 
resolution – transmission electron microscope (HR-TEM, JEM-3010, JEOL Ltd.) 
and Cs corrected STEM with Cold FEG (JEM-ARM200F, JEOL Ltd.) and the 
images were collected by Gatan Digital Camera (MSC-794) coupled to the 
microscope. XPS spectra for Gr/SiO2 were obtained by Kα XPS system (Thermo-
Scientific) with an X-ray mono-chromator (Al Kα Microfocused depth profiling 
EX06 Ion Source) with a spot size of 30 – 400 μm. 
DCFH-DA Fluorescence Measurements. The generation of secondary reactive 




dichlorofluorescin diacetate (DCFH-DA) probe (Sigma Aldrch, Ex/Em: 495 
nm/529 nm, 2 μM).
16
 The measurements for all test groups were performed after 
designated amounts of incubation periods with 5 ml of total volume. 
Ion-exchange HPLC Analysis. For the analysis of oxidative destruction of 
phenols, a hydrogen column (Aminex 87H column, 300x10 mm, Bio-Rad, USA) 
ion-exchange high performance liquid chromatography (HPLC, Dionex 
Ultimate3000) was utilised. Total injection volume was set to 10 μl in all test 
samples with 0.01 N H2SO4 eluent and the flow rate of 0.5 ml/min. Time-resolved 
HPLC analyses were performed over 90 minutes of injection time, and the 
intermediate structures were identified with the RI detector (ERC, 
RefractoMAX520, Japan). The identification of produced organic acid was carried 
out by the organic acid analysis coupled to the HPLC, based on the reference peaks 
and the retention times. 
pH and Temperature Measurements. During graphene-based phenol degradation 
process, the pH and temperature changes were monitored by a pH meter equipped 
with a digital thermometer (Trans instruments, BP3001). The changes were 
measured 0, 1, 3, 6, 12, 24 hours post-incubation. The values were recorded after 5 
minutes of each time point for stabilisation.  
X-ray Photoelectron Spectroscopy Analysis. XPS spectra for Gr/SiO2 were 
obtained by Kα XPS system (Thermo-Scientific) with an X-ray mono chromator 








1.6. Supplementary Information 
 
Figure 2-S1. (a) Representative SEM and (b) HRTEM images of the monolayer graphene 






Figure 2-S2. (a) HPLC analysis of hydrogen peroxide (100 mM) and phenols (1 mM). 
Hydrogen peroxide show strong, broad signals peaking at 7.43 and 8.65 minutes. (b) Time-
dependent HPLC analysis and (c) quantified intensities with 9 cm
2
 graphene film after 0, 3, 





Figure 2-S3. C1s (left) and O1s (right) XPS analysis pre- and post-phenol degradation 
respectively from the top. The characteristic C1s signals exhibited distinctive atomic ratio 
changes from 0.12 → 0.10, 0.2 → 0.22, 0.06 → 0.04 and 0.62 → 0.64 respectively at 289 eV 
(O-C=O), 286.8 eV (C=O), 286.1 eV (C-O) and 285 eV (Csp2). Likewise, the characteristic 
O1s signals displayed atomic ratio changes from 0.04 → 0.04 and 0.96 → 0.96 at 535 eV (C-
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Graphene Quantum Dots Prevent  




Though emerging evidence indicates that the pathogenesis of Parkinson’s disease is 




of α-synuclein (α-syn) 
aggregates in the midbrain, no anti-aggregation agents have been successful at 
treating the disease in the clinic. Here, we show that graphene quantum dots 
(GQDs) inhibit fibrillization of α-syn and interact directly with mature fibrils, 
triggering their disaggregation. Moreover, GQDs can rescue neuronal death and 
synaptic loss, reduce Lewy body and Lewy neurite formation, ameliorate 
mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn 
pathology provoked by α-syn preformed fibrils
5,6
. We observe, in vivo, that GQDs 
penetrate the blood–brain barrier and protect against dopamine neuron loss induced 
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1.2. Results and Discussion 
 
Figure 3-1. Effect of GQDs on α-syn fibrillization and fibril disaggregation. a, Schematic 
representation of α-syn fibrillization (5 mg/ml α-syn monomers) and disaggregation (5 
mg/ml α-syn fibrils) in the presence and absence of GQDs (5 mg/ml). b,c, Kinetics of α-syn 
fibrillization using aliquots of the reaction monitored by ThT fluorescence (b) and turbidity 
assays (c) (n=4 biologically independent samples; two-way analysis of variance (ANOVA) 
with a post hoc Bonferroni test, ***P < 0.001; error bars are standard deviation, s.d.). Mean 
values and P values are provided in Supplementary Table 1. d, TEM images of α-syn after 
fibrillization in the absence (left) and presence (right) of GQDs. e,f, Kinetics of preformed 
α-syn fibrils after incubation with GQDs using aliquots of the reaction monitored by ThT 
fluorescence (e) and turbidity assays at various time points (f) (n=4 biologically 
independent samples; two-way ANOVA with a post hoc Bonferroni test, ***P < 0.001; 
error bars are s.d.). Mean values and P values are provided in Supplementary Table 1. g, 
Quantifications of the end-to-end length and number of α-syn fibrils per μm
2
. Mean values 
of end-to-end length are 937.84, 245.52, 123.13, 66.27 and 51.02 nm at 0, 6, 12, 24 and 72 




0.0001 at 6, 12, 24 and 72 h; error bars are s.d.). Mean values of number are 15.53, 37.01, 
63.83, 97.52 and 44.38 per μm
2
 at 0, 6, 12, 24 and 72 h (n=6, biologically independent 
samples; one-way ANOVA with a post hoc Bonferroni test, P = 0.0483, P < 0.0001, P < 
0.0001 and P = 0.0050 at 6, 12, 24 and 72 h, respectively; error bars are s.d.). h, Amount of 
remaining α-syn fibrils (as % of number at 0 h), determined by multiplying the end-to-end 
length and number of α-syn fibrils at the same time points (0, 6, 12, 24 and 72 h) in the 
presence of GQDs. Mean values are 100.00, 47.33, 42.00, 36.67 and 13.83 at 0, 6, 12, 24 
and 72 h (n=6, biologically independent samples; one-way ANOVA with a post hoc 
Bonferroni test, error bars are s.d.). i, TEM images of preformed α-syn fibrils at various 
time points (6 and 12 h, 1, 3 and 7 days) in the absence (top) and presence (bottom) of 
GQDs. j, Representative image of α-syn fibrils dot-blot assay at various time points (0 and 
12 h, 1, 3 and 7 days) with α-syn filament specific antibody. These experiments were 
independently repeated three times with similar results. k, BN–PAGE analysis of α-syn, 
prepared with aliquots of reaction run at various time points (0, 3, 6 and 12 h, 1, 3 and 7 
days). These experiments were independently repeated three times with similar results. 
 
Following the synthesis and analysis of graphene quantum dots (GQDs) 
(Fig. 3-S2a–c,e), we investigated the potential role of these in inhibiting α-
synuclein (α-syn) fibrillization and disaggregating fibrils (Fig. 3-1 a). In the 
absence of GQDs, α-syn monomers assembled into mature fibrils, as assessed by 
thioflavin T (ThT) fluorescence (Fig. 3-1 b), turbidity assays (Fig. 3-1 c) and 
transmission electron microscopy (TEM) analysis (Fig. 3-1 d). The same 
assessments showed that the GQDs predominantly inhibited α-syn fibrillization. 
Moreover, GQDs induced the dissociation of α-syn fibrils into short fragments (Fig. 
3-1 e–i and Fig. 3-S3 a), with the average length of the fragments shortening from 
1 μm to 235 nm and 70 nm after 6 and 24 h, respectively (Fig. 3-1 g,i). The average 
number of the shortened fragments increased during the first 24 h of incubation, 
suggesting that the fibrils had dissociated from the inner parts of the α-syn fibrils 
(Fig. 3-1 h). However, the number of fragments started to decrease at day 3 and 




over the course of time (Fig. 3-1 i). Time-dependent atomic force microscopy 
(AFM) images show the same dissociation process, where GQDs and fibrils can be 
differentiated by their distinguishing height profiles (Fig. 3-S3 b). Dot-blot assay 
and blue native polyacrylamide gel electrophoresis (BN–PAGE) analysis also 
revealed that incubation with GQDs results in the gradual reduction of fibrils in a 
time-dependent manner (Fig. 3-1 j,k). Similar effects of GQDs were also observed 
on sonicated α-syn preformed fibrils (PFFs), which produced a higher population 
of monomers as the incubation period progressed (Fig. 3-S4 a–c). 
To visualize the interaction between GQDs and α-syn fibrils, GQDs were 
functionalized with PEGylated biotin (Fig. 3-S2 d–g). Using streptavidin-tagged 
ultra-small gold particles and TEM, direct binding between GQDs and α-syn fibrils 





quantum coherence correlation (HSQC) NMR spectroscopy was utilized to further 




 for GQDs and their molecular 
interactions at the residue level in solution. Co-incubation with GQDs led to many 
residues with large chemical shifts while others had entirely disappeared (Fig. 3-
S5). The residues that disappeared were centred on the N-terminal region, implying 
that the initial binding between GQDs and α-syn is largely driven by the charge 
interaction between the negatively charged carboxyl groups of the GQDs (Fig. 3-
S2 e) and the positively charged region of α-syn (Fig. 3-2 c).  
To better understand and elucidate the mechanism of α-syn fibril 
dissociation by GQDs, a 200 ns molecular dynamics (MD) simulation was 
performed. The structure of the α-syn fibril was adopted from the recently reported 
ssNMR (solid-state nuclear magnetic resonance) structure of pathologic human α-
syn
9








Figure 3-2. Detailed analysis of the interaction between GQDs and mature α-syn fibrils 
during the dissociation process. a, TEM images for binding between biotinylated GQDs and 
α-syn fibrils with low and high magnifications. Arrowheads indicate biotinylated GQDs 
enhanced with ultra-small gold–streptavidin nanoparticles. b, Quantification of the average 
width of α-syn fibrils during the disaggregation process after 1 h of incubation (mean ± 
s.d.): 14.74 ± 0.70 nm and 17.42 ± 0.83 nm for fibrils and fibrils + GQDs–biotin (n=20 for 





N HSQC spectra. The decreased intensity ratio of NMR chemical shifts is 
presented for each residue after binding with GQDs. d, Time course simulation dynamics of 
the interaction between GQDs and mature α-syn fibrils, and 65 ns snapshot image (bottom 
right) of the interaction between GQDs and mature α-syn fibrils with designated sidechains 
attributed for the major binding force. e, Time-dependent plots for r.m.s.d. of atomic 
positions, SASA for the α-syn fibril only group and α-syn fibril and GQDs group, total 
potential energy (Δ Utot), electrostatic energy (Δ Eelec) and van der Waals energy (Δ Evan) 
for α-syn fibril and GQDs group, respectively (from the top). f, Time-dependent secondary 
structure plot calculated by the DSSP algorithm. g, CD spectra of α-syn monomers and α-
syn fibrils without and with GQDs after 7 days of incubation. h, Fractional secondary 
structure contents ratio of α-syn fibrils and α-syn fibrils disaggregated by GQDs calculated 
using the algorithm CONTIN/LL (n=5 biologically independent samples). Data presented 
as mean ± s.d. (fibrils versus fibrils + GQDs (% of content); coil: 20.13 ± 5.74 versus 24.58 
± 3.64; β-turn: 22.39 ± 4.62 versus 25.89 ± 1.34; β-sheet: 53.30 ± 3.53 versus 29.76 ± 3.35; 
α-helix: 4.17 ± 1.25 versus 19.74 ± 1.52). 
 
(NAC) domain (residues 71 to 82) was taken, as it is essential for α-syn 
fibrillization
10
. Following instantaneous binding between the GQDs and the N 
terminal cross-β part of α-syn at 1 ns, the β-sheet structure of the outer monomer 
was completely destroyed after 50 ns; its C-terminal part was released from the 
core and interacted with the opposite plane of the GQDs (Fig. 3-2 d). The time-
dependent secondary structure plot, calculated by the dictionary of secondary 
structure of proteins (DSSP) algorithm, also shows a decrease in the β-sheet 
component of the outer monomer from 50 ns onwards, indicating critical structural 




square deviation (r.m.s.d.) of atomic positions, solvent accessible surface area 
(SASA) and the interaction energies of the fibril were plotted against time (Fig. 3-2 
e). Though massive changes in the r.m.s.d. and SASA values are observed after 50 
ns, the changes in the total potential energy (Δ Utot) show a slight, yet continuous 
decline. It is confirmed that the major stabilizing/dissociation force is attributed to 
strong hydrophobic interactions, as changes in the van der Waals energy (Δ Evan) 
show a decline and the electrostatic energy (Δ Eelec) remains steady. The results are 
consistent with the 65 ns snapshot, which shows strong hydrophobic interactions 
between the GQDs’ basal plane and valine residues (Fig. 3-2 d). To further analyse 
the changes in the secondary structure of α-syn fibrils, circular dichroism (CD) 
spectra were obtained and the fractional secondary structures were analysed using 
the algorithm CONTIN/LL
11,12 
(Fig. 3-2 g,h). After 7 days, changes in the 
secondary structure were observed, with the β-sheet component decreasing from 
53.3 ± 3.5% to 29.8 ± 3.4% and the α-helix/random coil components increasing 
from 4.2 ± 1.2% to 19.8 ± 1.5% and 20.1 ± 5.7% to 24.6 ± 3.6%, respectively. 
Collectively, the interaction between GQDs and α-syn is initiated by the charge 
interactions, and fibril dissociation is driven chiefly by hydrophobic interactions, 
accompanied by structural changes. 
Based on these results, the potential role of GQDs in preventing α-syn 
PFF-induced pathology was explored in primary neurons. α-syn PFF treatment 
leads to critical cell death, as assessed by various cell viability assays including 
terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) (Fig. 3-3 
a and Fig. 3-S6 a), alamarBlue (Fig. 3-3 b), lactate dehydrogenase (LDH) (Fig. 3-3 
c) and neurite outgrowth assays (Fig. 3-S6 b–d). In contrast, the presence of GQDs 





Figure 3-3. Effect of GQDs on α-syn PFF-induced neuronal death, pathology and 
transmission in vitro. a–c, Neuronal death assessed by TUNEL (a), alamarBlue (b) and 
LDH assays (c) treated with α-syn PFFs (1 μg/ml) in the absence and presence of GQDs (1 
μg/ml) in 10 DIV mouse cortical neurons for 7 days. Mean values of TUNEL (% of 
TUNEL+ cells) are 18.94, 15.86, 61.39 and 30.45 for PBS, GQDs, PFFs and PFFs + 
GQDs; mean values of alamarBlue (% of control) are 100.00, 99.16, 49.33 and 78.86 for 
PBS, GQDs, PFFs and PFFs + GQDs; mean values of LDH assay (% of control) are 100.00, 
95.43, 154.58 and 113.33 for PBS, GQDs, PFFs and PFFs + GQDs (n=6 biologically 




error bars are s.d.). d, Representative immunoblot levels with p-α-syn antibody. e, 
Quantifications of the SDS-insoluble fraction normalized to the levels of β-actin. Mean 
values are 1.00, 1.49, 16.35 and 6.86 for PBS, GQDs, PFFs and PFFs + GQDs (n=6 
biologically independent samples; two-way ANOVA with post hoc Bonferroni test; NS, not 
significant; error bars are s.d.). f, Representative p-α-syn immunostaining micrographs with 
p-α-syn antibody. g, Quantifications of p-α-syn immunofluorescence intensities normalized 
to PBS control. Mean values are 1.00, 0.99, 13.62 and 4.69 for PBS, GQDs, PFFs and PFFs 
+ GQDs (n=6 biologically independent samples; two-way ANOVA with post hoc 
Bonferroni test; NS, not significant; error bars are s.d.). h, Schematic representation of the 
microfluidic device for the transmission of pathologic α-syn, composed of three connected 
chambers. i, Representative images of p-α-syn immunostained neurons in the microfluidic 
device 14 days post α-syn PFFs addition. j, Quantifications of p-α-syn immunofluorescence 
intensities. Areas occupied by p-α-syn were measured in each chamber. Mean values of 
chamber 1 are 15.67, 3.12 and 4.52 for PFFs, PFFs + GQDs (C1) and PFFs + GQDs (C2); 
mean values of chamber 2 are 8.52, 2.56 and 3.90 for PFFs, PFFs + GQDs (C1) and PFFs + 
GQDs (C2); mean values of chamber 3 are 6.04, 1.72 and 1.67 for PFFs, PFFs + GQDs 
(C1) and PFFs + GQDs (C2) (n=6 biologically independent samples; two-way ANOVA 
with post hoc Bonferroni test; NS, not significant; error bars are s.d.). 
 
In addition, treatment of α-syn PFFs leads to a reduction in synaptic proteins such 
as SNAP25 and VAMP2, suggesting severe dysfunction in neuronal networks
5
. 
Importantly, GQDs restore the reduced synaptic protein levels provoked by α-syn 
PFFs (Fig. 3-S6 e–g). Mitochondrial dysfunction is another major pathological 
hallmark during the progression of Parkinson’s disease
13
. The effect of GQDs on 
mitochondrial dysfunction and subsequent cellular respiration was thus 
investigated by performing oxidative stress marker 8-hydroxyguanosine (8-OHG) 
staining, mitochondrial complex I activity assay, MitoTracker staining, TEM 
analysis and seahorse assay (Fig. 3-S7). The treatment of α-syn PFFs causes 
mitochondrial damage characterized by shrinkage, decreased oxygen consumption 
rate and elevated reactive oxygen species (ROS) levels in neurons, but the addition 




 The role of GQDs on α-syn PFF-induced Lewy body (LB)/Lewy neurite 
(LN)-like pathology was then evaluated. After 7 days of α-syn PFF treatment, 
accumulation of α-syn in the SDS-insoluble fraction was analysed by western blot, 
showing decreased phosphorylated α-syn (p-α-syn) accumulation with GQDs (Fig. 
3-3 d,e). In addition, p-α-syn immunoreactivity is increased in primary neurons by 
α-syn PFFs, whereas it is barely detectable in primary neurons treated with GQDs 
as assessed by α-syn phosphoserine 129 immunostaining (Fig. 3-3 f,g). To 
investigate the effect of treatment time on α-syn pathology, GQDs were treated 
simultaneously with and 3 days pre/post α-syn PFF additions. Though the toxicity 
amelioration and inhibition effects on p-α-syn accumulation were slightly weaker 
when GQDs were applied 3 days after α-syn PFF injection, the collective results 
practically show consistent effects (Fig. 3-S8 a–f). To verify the cellular 
localization of the inhibitory effects of GQDs, GQDs, α-syn PFFs and the 
lysosome were distinctively labelled with fluorescent probes for live imaging (Fig. 
3-S8 g,h). As shown from the time-course snapshots, fluorescence signals for α-syn 
PFFs and GQDs are co-localized within the lysosome, where the signal for α-syn 
PFFs gradually decreases and that of GQDs increases with time. It can be 
presumed that both GQDs and α-syn PFFs are endocytosed, and the disaggregation 
of fibrillized α-syn takes place in the lysosome by the surrounding GQDs. 
 One of the key features of the α-syn PFFs neuron model is neuron-to-
neuron transmission of pathologic α-syn aggregates
5
. To examine the effect of 
GQDs, a triple-compartment microfluidic culture device was used, where 
transmission between neurons takes place sequentially from C1 to C3 (Fig. 3-3 h). 
At 14 days post-α-syn PFF treatment, the levels of p-α-syn were visualized by 




greatly reduced in C2 and C3 with the presence of GQDs in C1, which suggests 
that GQDs prevent the seeds of endogenous α-syn from forming aggregates (Fig. 3-
3 i,j). Also, the levels of p-α-syn immunoreactivity are lowered in C2 and C3 when 
GQDs are added to C2, indicating that GQDs block the transmission of pathologic 
α-syn to neighbouring neurons. 
 To address whether GQDs possess neuroprotective effects against α-syn 
PFF-induced transmission and toxicity in vivo, α-syn PFFs were stereotaxically 
injected into the striatum of wild-type (WT) mice and GQDs were administered 
biweekly (that is, every two weeks) via intraperitoneal (i.p.) injection (Fig. 3-4a). 
Foremost, we sought to verify the blood–brain barrier (BBB) permeability of 
GQDs by using an in vitro BBB model
14
 (Fig. 3-S9 a,b). The form and 
functionality of the BBB model were subsequently confirmed by measuring the 
transepithelial electrical resistance (TEER) and dextran fluorescence intensity (Fig. 
3-S9 c,d). The in vitro permeability of GQDs was then ascertained by measuring 
the fluorescence intensity on the brain side. Intriguingly, the fluorescence signal 
gradually increased with time, and showed 100% permeability after 24 h (Fig. 3-S9 
e). To corroborate the penetration process visually, GQD–biotin was utilized and 
linked to streptavidin–quantum dots for live fluorescence imaging. Before the 
study, the functional behaviour of GQD–biotin was assessed, and was found to 
exhibit similar BBB penetration rates and fibril dissociation effects as those of 
pristine GQDs (Fig. 3-S9 e–g). Live fluorescence imaging showed that the GQD–
biotin complex is localized in the lysosome of both brain microvascular endothelial 
cells (BMECs) and astrocytes, and disappears through the exosome (Fig. 3-S9 h,i). 
This suggests that GQDs are endocytosed into BMECs on the blood side and 





Figure 3-4. Effect of GQDs on α-syn-induced pathologies in vivo. a, Schematic illustration 
of injection coordinates of α-syn PFFs (5 μg) for stereotaxic intrastriatal injection in 
C57BL/6 mice. As a treatment, 50 μg of GQDs or PBS were i.p. injected biweekly for 6 
months. AP, anteroposterior; ML, mediolateral; DV, dorsoventral; Ctx, cortex; STR, 
striatum; IHC, immunohistochemistry. b, Representative TH immunohistochemistry images 
in the substantia nigra of α-syn PFF-injected hemisphere in the absence (top) and presence 
(bottom) of GQDs. c, Stereological counting of the number of TH- and Nissl-positive 
neurons in the substantia nigra via unbiased stereological analysis after 6 months of α-syn 
PFF injection with and without GQDs injection. Mean values are 5,061, 5,096, 3,155 and 
4,080 Nissl-positive neurons; 4,039, 4,068, 2,327 and 3,221 TH-positive neurons (n=6 
biologically independent animals; two-way ANOVA with a post hoc Bonferroni test; NS, 
not significant; error bars are s.d.). d, Representative TH immunohistochemistry images in 
the striatum of α-syn PFF-injected hemisphere. e, Quantifications of TH-immunopositive 




1.00, 1.03, 0.42 and 0.90 for PBS + PBS, PBS + GQDs, PFFs + PBS and PFFs + GQDs 
(n=6 biologically independent animals; two-way ANOVA with a post hoc Bonferroni test; 
NS, not significant; error bars are s.d.). f, Assessments of the behavioural deficits measured 
by the use of forepaws in the cylinder test. Mean values (% of ticks) are 51.00, 51.67, 29.83 
and 44.17 for PBS + PBS, PBS + GQDs, PFFs + PBS, and PFFs + GQDs (n=6 biologically 
independent animals; two-way ANOVA with a post hoc Bonferroni test; NS, not 
significant; error bars are s.d.). g, Assessments of the behavioural deficits measured by the 
ability to grasp and descend from a pole. Mean values are 10.25, 11.38, 22.73 and 14.43 s 
for PBS + PBS, PBS + GQDs, PFFs + PBS and PFFs + GQDs (n=6 biologically 
independent animals; two-way ANOVA with a post hoc Bonferroni test; NS, not 
significant; error bars are s.d.). h, Representative p-α-syn immunostaining images in the 
striatum (STR) and substantia nigra (SN) of α-syn PFF-injected hemisphere. i, 
Quantifications of p-α-syn immunoreactive neurons in the striatum and substantia nigra. 
Mean values (number of inclusions) are 43.33 and 12.50 for PFFs + PBS and PFFs + GQDs 
of striatum (STR); 17.67 and 8.00 for PFFs + PBS and PFFs + GQDs of substantia nigra 
(n=6 biologically independent animals; two-tailed Student’s t-test; error bars are s.d.). j, 
Distribution of LB/LN-like pathology in the CNS of α-syn PFF-injected hemisphere (p-α-
syn positive neurons, red dots; p-α-syn positive neurites, red lines). 
 
released through the exosome. The in vivo permeability of the BBB was studied by 
using GQD–biotin for immunohistochemical analysis of the brain. After i.p. 
injection, a considerable amount of GQD–biotin was detected in the entire central 
nervous system (CNS) region, including the olfactory bulb, neocortex, midbrain 
and cerebellum, indicating that GQDs also have the ability to penetrate the BBB in 
vivo (Fig. 3-S9 j–n). 
At 180 days post-α-syn PFF injection, decreased tyrosine hydroxylase 
(TH)- and Nissl-positive neurons in the substantia nigra are observed in WT mice. 
On the other hand, mice administered with GQDs are protected against α-syn PFF-
induced loss of dopaminergic neurons (Fig. 3-4 b,c). Furthermore, α-syn PFFs 
provoke a loss of TH-positive striatal fibre neurons, while GQDs also prevent loss 




assessed by cylinder and pole tests. Mice with GQD injection exhibited alleviated 
motor deficit, showing balanced use of both forepaws and decreased pole 
descending time, respectively, in the cylinder and pole tests (Fig. 3-4 f,g). 
The levels of p-α-syn, a marker of LBs/LNs, were visualized in the 
striatum and substantia nigra of α-syn PFF-injected mice. Stereotaxically injected 
α-syn PFFs provoke accumulation of p-α-syn in the striatum and substantia nigra, 
but administration of GQDs reduces p-α-syn levels (Fig. 3-4 h,i). The injection of 
α-syn PFFs in the striatum also leads to propagation of α-syn aggregates 
throughout the CNS region, whereas GQDs inhibit the transmission of pathological 
α-syn (Fig. 3-4 j). In addition, GQDs injection ameliorates α-syn PFF-induced 
gliosis in the substantia nigra accompanying decreased microglia density and glial 
fibrillary acidic protein (GFAP) levels in astrocytes (Fig. 3-S10). To further 
corroborate the therapeutic potential of GQDs against a transgenic in vivo 
Parkinson’s disease model, 6 month human A53T α-syn transgenic mice
15
 were 
administered biweekly with GQDs for 4 months (Fig. 3-S11 a). Similar to the α-
syn PFF-induced model, GQDs administration reduces p-α-syn levels in the CNS 
region (Fig. 3-S11 b–d), as well as the microglia density and GFAP levels in 
astrocytes in the transgenic model (Fig. 3-S11 h–k). GQDs treatment also reduces 
the α-syn aggregates induced by overexpression of human A53T α-syn in HEK293 
cells
16
 Fig. 3-S11 l,m). GQDs alleviate behavioural defects in the hA53T α-syn Tg 
mice as well, as monitored by the pole and clasping tests (Fig. 3-S11 e–g). It must 
be noted that there is no loss of dopamine neurons, glial cells activation, 
behavioural abnormalities and organ damage in mice with 6 months of prolonged 
GQDs injection, demonstrating that GQDs manifest no appreciable long-term in 





A few previous reports have discussed the potential therapeutic role of 
graphene oxides (GOs) and GQDs against Alzheimer’s disease by inhibiting the 
fibrillization of beta-amyloid (Aβ) peptides
17–19
. In addition, computational 
evidence suggests that a hydrophobic graphene sheet could cause the destruction of 
amyloid fibrils
20
. To compare the therapeutic efficacy of GQDs with the results of 
previous studies, nano-sized GOs (nano-GOs, ranging from ~5 to 20 nm) and 
reduced GQDs (rGQDs) were prepared (Fig. 3-S13 a,b). As shown from the 
Fourier-transform infrared (FT–IR) spectra, pristine GQDs exhibit abundant 
carboxyl groups, while nano-GOs and rGQDs show much lower carboxyl 
group:aromatic carbon double bond ratios. The difference in the carboxyl 
functional group contents is directly reflected in cell viability assays, where nano-
GOs and rGQDs show serious in vitro toxicities, unlike GQDs (Fig. 3-S13 c,d). 
Moreover, nano-GOs and rGQDs exhibit considerably weaker fibril-dissociation 
effects than GQDs (Fig. 3-S13 e–g). This can presumably be attributed to the 




N HSQC analysis that the positively charged N-terminal region is the initial, 
but chief binding site with GQDs. It must also be noted that the BBB permeability 
of nano-GOs is much lower than that of GQDs and rGQDs, suggesting that size 
may be a decisive factor for the BBB permeability of graphene-based nanoparticles 
(Fig. 3-S13 h). Collectively, our results show that GQDs are the optimal 
therapeutic candidate for anti-Parkinson’s disease and related α-synucleinopathies 
therapy, with no appreciable in vitro and long-term in vivo toxicity, respectable 






To open new venues in clinical drug development against Parkinson’s 
disease, a candidate desirably features outstanding anti-aggregation and 
dissociation properties towards α-syn aggregates, without severe toxicity. GQDs 
are found to bind to α-syn fibrils, inhibit transmission and possess unique 
neuroprotective effects against the neuropathological α-syn aggregates/fibrils in 
both in vitro and in vivo models. It is expected that GQD-based drugs with 
appropriate modifications might provide a clue to support the development of new 
therapeutic agents for abnormal protein aggregation-related neurological disorders 
including Parkinson’s disease. 
 
1.4. Experimental 
Preparation of GQDs. GQDs were synthesized by placing 0.9 g of carbon fibres 
(Carbon Make) in a mixture of strong acid (300 ml sulphuric acid and 100 ml nitric 
acid; Samchun Chemical) at 80 °C for 24 h. After acid removal, the solution was 
vacuum-filtered with a porous inorganic membrane filter (cat. no. 6809-5002, 
Whatman-Anodisc 47; GE Healthcare) to discard large particles. The solution was 
then subjected to rotary evaporation to yield the final product in powder form. 
AFM imaging. For AFM imaging, 5 μl of GQDs (10 μg/ml) and α-syn fibrils (10 
μg/ml) were prepared on a silicon substrate. The analyses were performed with an 
XE-100 AFM (Park Systems) via non-contact mode (scan size: 25 μm
2
 and scan 
rate: 0.8 Hz). The images were acquired by equipped XE data acquisition program 
(XEP 1.8.0). 




pellet method (no. of scans, 32; resolution, 4; wavenumber range, 4,000–40 cm
−1
). 
The analysis was performed with a Nicolet 6700 FT–IR spectrometer (Thermo 
Scientific). 
ThT and turbidity assays. Turbidity and ThT assays were used for the 
measurement of α-syn fibrils. For the ThT assay, 50 μl of each sample was 
centrifuged at 16,000 g for 30 min. The pellet was then re-suspended in 200 μl of 
ThT assay solution consisted of 25 μM ThT (cat. no. T3516, Sigma-Aldrich) in 10 
mM glycine buffer (pH 9.0). The amount of α-syn fibrils was determined by a 
fluorescence spectrophotometer with the ThT fluorescence measured at 482 nm 
(excitation at 440 nm). For the turbidity assay, α-syn fibrils were diluted with PBS 
(1:10). The diluted α-syn fibrils were loaded into the wells of Corning 96-well 
plates. The turbidity of each sample was determined by a microplate reader 
(absorbance at 360 nm). 
TEM imaging. The α-syn fibrils were adsorbed to glow discharge grids (EMS, 400 
mesh carbon-coated copper grids) for 2 min and rinsed with three drops of Tris-
HCl (50 mM, pH 7.4). The rinsed grids were floated with two drops of 0.75% 
uranyl formate. After drying, the images were captured by a Phillips CM 120 TEM 
(80 kV) with an AMT ER-80 charge-coupled device (8 megapixel). For primary 
cultured neurons, cells were seeded onto a poly-d-lysine-coated 35 mm dish at a 
density of 100,000 cells per well. Neurons were treated with 1 μg/ml of PFFs with 
or without 1 μg/ml of GQDs at days in vitro (DIV) 10. At DIV 17, cells were 
washed with 1% sodium nitrite containing PBS (pH 7.4) and fixed with 3% PFA, 
100 mM cacodylate, 1.5% glutaraldehyde, 2.5% sucrose containing fixative (pH 
7.4) for 1 h. TEM images were captured by a Philips EM 410 TEM with a Soft 




Dot-blot assays. Tris-buffered saline (TBS)-wetted nitrocellulose membrane (NC 
membrane, 0.45 μm pore) was mounted on the Bio-Dot microfiltration apparatus 
(cat. no. 1706545, Bio-Rad). The samples were loaded into the wells of a 
microfiltration apparatus under mild vacuum. After washing with TBS, the NC 
membranes were blocked with 0.5% Tween-20 and 5% non-fat dry milk containing 
TBS blocking buffer and attached with anti-α-syn filament antibody (cat. no. 
ab209538, 1:1,000, abcam) at 4 °C for 12 h. After incubation with horseradish 
peroxidase (HRP)-conjugated rabbit second antibodies (GE Healthcare) at room 
temperature for 1 h, the signals from α-syn aggregates were then visualized by 
enhanced chemiluminescence (ECL) solution. The data were analysed with ImageJ 
software (http://rsb.info.nih.gov/ij/, NIH). 
BN–PAGE and SDS–PAGE. For BN–PAGE, α-syn fibrils and α-syn PFFs were 
prepared using a NativePAGE sample prep kit (cat. no. BN2008, Life 
Technologies) and run on NativePAGE Novex 4–16% bis–tris protein gels (cat. no. 
BN1002Box, Life Technologies) at 200 V for 90 min. Then, 50 mM tricine, 15 
mM Bis–Tris, 0.02% Brilliant Blue G (pH 7.0) containing cathode buffer and 50 
mM Bis-Tris (pH 7.0) containing anode buffer were used for BN–PAGE. After 
BN–PAGE, gels were stained with a SilverQuest silver staining kit (cat. no. 
LC6070, Life Technologies), following the manufacturer’s protocols. For SDS–
PAGE, 10 DIV cortical neurons were treated with α-syn PFFs (5 μg/ml) in the 
presence and absence of GQDs (5 μg/ml) for 7 days. At DIV 17, the soluble 
proteins were isolated from the neurons with a 1% TX-100, protease inhibitors and 
phosphatase inhibitors cocktail (cat. no. PPC1010, Sigma-Aldrich) containing 
sample buffer. For insoluble protein isolation, the lysates of neurons were 




washed and suspended in 2% SDS containing PBS for preparation of insoluble 
protein. Laemmli sample buffer (2×, cat. no. 1610737, Bio-Rad) was used to dilute 
the soluble and insoluble protein samples. For SDS–PAGE, 20 μg of soluble or 
insoluble proteins was loaded onto the wells of Novex 8–16% tris-glycine gel (cat. 
no. XP08160BOX, Life Technologies) and electrophoresis was performed at 130 V 
for 85 min. After transfer of proteins onto the NC membrane, it was blocked with 
0.1% Tween-20 and 5% non-fat dry milk containing TBS for 1 h and incubated at 
4 °C overnight with SNAP25 (cat. no. 111-002, 1:2,000, Synaptic Systems), 
VAMP2 (cat. no. ab3347, 1:1,000, abcam) or anti-pS129-α-syn antibodies (cat. no. 
ab59264, 1:1,000, abcam). The NC membranes were then incubated with HRP-
conjugated mouse or rabbit secondary antibodies (GE Healthcare) at room 
temperature for 1 h and visualized by ECL solution. The signals were measured by 
ImageJ software (http://rsb.info.nih.gov/ij/, NIH). 
Preparation of sonicated α-syn PFFs. The α-syn PFFs were prepared following 
the method published in ref. 21. Briefly, full-length mouse recombinant α-syn was 
cloned using the pRK172 bacterial expression vector. The plasmids were then 
transformed into BL21(DE3)RIL-competent Escherichia coli (cat. no. 230245, Life 
Technologies). The α-syn monomers were purified through several steps including 
dialysis, anion exchange and size exclusion chromatography after bacterial growth. 
In vitro α-syn fibrils were assembled in an Eppendorf orbital mixer (cat. no. 
538400020) under specific agitation conditions (1,000 r.p.m., 37 °C, 7 days). For 
the formation of preformed fibrils, α-syn fibrils were sonicated for a total of 60 
pulses (20% amplitude, 0.5 s on, 0.5 s off) with a 1/8’’ probe sonicator. 
Biotinylation of GQDs and binding assay. GQDs (50 mg) were dissolved in 




dimethylaminopropyl)-N’’-ethylcarbodiimide hydrochloride; cat. no. 03449, 
Sigma-Aldrich) was subsequently added to replace the carboxyl groups. After 1 h 
of reaction with vigorous stirring, 25 mg of EZ-Link amine-PEG3-biotin (cat. no. 
21347; Thermo Scientific) was added to EDC-activated GQDs. The solution was 
then subjected to dialysis and rotary evaporation to yield the final product in 
powder form. For the binding assay between GQDs and α-syn fibrils, 5 mg/ml of 
α-syn fibrils were incubated with 5 mg/ml of biotinylated GQDs and streptavidin 
conjugated 0.8 nm ultra-small gold particles (cat. no. 800.099, Aurion) for 1 h. 
Next, the streptavidin-conjugated ultra-small gold particles bound with high 
affinity to biotinylated-GQDs were enhanced with GoldEnhance EM Plus solution 
(cat.no. 2114, Nanoprobes) for 5 min. Non-reacted solution was removed by a 100 
kDa molecular weight cut-off spin column (cat. no. UFC510024, Millipore-Sigma), 
followed by TEM analysis. 
Purification of 
15
N-labelled α-syn. The α-syn gene cloned in pRK172 vector was 
transformed into E. coli BL21 (DE3) for α-syn overexpression. For the preparation 
of isotope-labelled α-syn, cells were grown in M9 minimal medium containing 0.5 
g of 
15
NH4Cl and 1 g of 
13
C glucose (Cambridge Isotope Laboratory) per litre at 
37 °C with 100 μg/ml ampicillin. After induction with isopropyl β-d-1 
thiogalactopyranoside (IPTG), the heat-treated cell lysate was subjected to 
successive purifications using DEAE-Sephacel anion-exchange, Sephacryl S-200 
size-exclusion and S-Sepharose cation-exchange chromatography. The purified α-
syn was dialysed against 12 L of fresh 20 mM 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer (pH 6.5) three times, and stored in aliquots at a concentration of 
1 mg/ml at -80 °C. The sample was concentrated to 5 mg/ml using Nanosep 10K 




NMR spectroscopy analysis. A detailed NMR study of the interaction between α-
syn and GQDs was performed using a 950 MHz spectrometer equipped with a 
cryo-genic probe (Bruker). 
15
N-labelled α-syn (5 mg/ml, 100 μl) was reacted with 
GQDs (5 mg/ml, 100 μl) under 37 °C shaking incubation at 1,000 r.p.m. for 3 days. 
15
N-labelled α-syn samples were prepared using 20 mM MES buffer (pH 6.5) 








N HSQC spectra of both α-
syn and GQD-reacted α-syn were acquired at 37 °C. The obtained data were 
processed by NMRPipe
22
 and analysed by Sparky
23
. 
Simulation details. The MS simulation (200 ns) was performed with Gromacs 5.1 
to examine the interaction between GQDs and α-syn fibrils at the molecular level
24
. 
The initial structure of the hydrophobic NAC domain (residues 71–82) of α-syn 
was adapted from the ssNMR structure (PDB ID: 2N0A) with CHARMM 
forcefield
25
, and the structure of the GQDs was designed with CGenFF
26
 by 
protocols from https://cgenff.paramchem.org. 
CD measurements. The α-syn fibrils (5 mg/ml, 100 μl) were mixed with GQDs 
solution (5 mg/ml, 100 μl) and depolymerized under 37 °C shaking incubation at 
1,000 r.p.m. for 7 days. For far-ultraviolet CD measurements, the sample was 
diluted (1/2) with deionized water. CD spectra between 190 and 260 nm were 
measured at 0.5 nm intervals using a J-815 spectropolarimeter (Jasco) and a 0.2-
mm-path-length quartz cuvette. The spectrum of the buffer solution was subtracted 
from the sample spectra. CD signals were normalized to the mean residue 




. The fractional secondary structure 
contents of the α-syn fibrils and depolymerized α-syn fibrils were calculated using 
the algorithm of CONTIN/LL on the DichroWeb online server 




reference set 7 on Dichroweb was employed, which is optimized for the 
wavelength range 190–240 nm. 
Primary neuron culture. Primary cortical neurons were isolated from the brain of 
embryonic day 15 C57BL/6 mice (Charles River) and seeded onto poly-d-lysine-
coated dishes (cat. no. P6407, Sigma-Aldrich). The cultured neurons were 
maintained with complete culture medium composed of B27 supplement (cat. no. 
17504044, Life Technologies), L-glutamine (cat. no. 25030149, Life Technologies) 
and neurobasal medium (cat. no. 21103049, Life Technologies) at 37 °C in a 7% 
CO2 incubator. To inhibit the growth of glial cells in the neuron culture, 30 μM of 
5-fluoro-2’-deoxyuridine (cat. no. F0503, Sigma-Aldrich) was added after 5 days 
of culture. 
Cell viability and cytotoxicity assays. For cell viability and cytotoxicity assays, 
primary cortical neurons were seeded onto poly-d-lysine-coated glass coverslips at 
a density of 10,000 cells per cm
2
. The cells were then incubated in a 7% CO2 
incubator at 37 °C with complete neuronal culture medium. The cytotoxicity was 
measured with α-syn PFFs (1 μg/ml) in the absence and presence of GQDs (1 
μg/ml) in 10 DIV primary mouse cortical neurons for 7 days. An LDH cytotoxicity 
assay kit (cat. no. 88954, Pierce) and TUNEL assay kit (cat. no. 12156792910, 
Roche) were used to measure cytotoxicity. The viability of mouse primary cortical 
neurons and SH-SY5Y cells was determined using an alamarBlue cell viability 
assay kit (cat. no. DAL1025, Molecular Probes) and a neurite outgrowth staining 
kit (cat. no. A15001, Molecular Probes), following the manufacturers’ instructions. 
In vitro immunofluorescence. Mouse primary cortical neurons were seeded at a 
density of 20,000 cells per cm
2
 onto poly-d-lysine-coated glass coverslips. After 




(NDS; cat. no. 017-000-121, Jackson ImmunoResearch), 2% bovine serum 
albumin (BSA; cat. no. A7030, Sigma-Aldrich) and 0.1% Triton X-100 (cat. no. 
T8787, Sigma-Aldrich) containing PBS at room temperature for 1 h. Subsequent 
incubations with anti-8-OHG (cat. no. ab62623, 1:1,000, abcam), anti-pS129-α-syn 
(cat. no. ab59264, 1:1,000, abcam) and anti-MAP2 (cat. no. MAB3418, 1:1,000, 
Millipore) antibodies were carried out overnight at 4 °C. The coverslips were 
washed with 0.1% Triton X-100 containing PBS and incubated with a mixture of 
FITC-conjugated (donkey anti-rabbit FITC, cat. no. 711-095-152; donkey anti-
mouse FITC, cat. no. 715-095-151, Jackson ImmunoResearch) and Cy3-conjugated 
(donkey anti-rabbit CY3, cat. no. 711-165-152; donkey antimouse CY3, cat. no. 
715-165-151, Jackson ImmunoResearch) second antibodies at room temperature 
for 1 h. The fluorescence images were captured using a Zeiss LSM 710 confocal 
microscope. 
Microfluidic chambers. Before being fixed to the microfluidic devices (triple-
chamber microfluidic devices, cat. no. TCND1000, Xona), the rectangular glass 
coverslips were prepared according to the method of ref. 5. Each chamber was 
plated at a density of 100,000 cells per chamber. At DIV 7, 0.5 μg of GQDs were 
added to chamber 1 (C1) or chamber 2 (C2) before treatment with 0.5 μg α-syn 
PFFs to C1. To regulate the direction of flow of the channels, a 50 μl difference in 
media volume was controlled through the chambers. At DIV 21, neurons in the 
chambers were fixed with 4% PFA containing PBS and blocked with 0.1% Triton 
X-100, 5% NDS and 2% BSA containing PBS at room temperature for 1 h. The 
chambers were then incubated with anti-pS129-α-syn (cat. no. ab59264, 1:1,000, 
abcam) and anti-MAP2 (cat. no. MAB3418, 1:1,000, Millipore) antibodies at 4 °C, 




the chambers were incubated in a mixture of FITC-conjugated (Jackson 
ImmunoResearch) and Cy3-conjugated (Jackson ImmunoResearch) second 
antibodies for 1 h at room temperature. The fluorescent images were captured 
using a LSM 710 Zeiss confocal microscope. 
Complex I activity assay. The commercial microplate assay kit (Cat#: ab109721; 
abcam) was used for measuring the complex I enzyme activity, following the 
manufacturer’s instruction. Briefly, primary cortical neurons were plated onto 
poly-d-lysine coated 6 cm dishes at a density of 1,000,000 cells/dish. Neurons were 
then treated with 1 μg/ml of α-syn PFFs with or without 1 μg/ml of GQDs at 10 
days in vitro. After 7-day treatment, the cytosolic proteins were extracted using 
1/10 volume detergent in PBS. The supernatant was isolated by centrifuging at 
12,000 × g for 20 mins from 5.5 mg/ml of samples. Isolated samples were loaded 
and incubated for 3 hours at RT, and rinsed twice with washing buffer. After 
adding a 200 μl assay solution, the mitochondrial complex 1 enzyme activity was 
measured at approximately 1-min intervals for 30 mins. 
Mitochondrial morphology assessment. Primary cultured cortical neurons were 
plated onto poly-d-lysine coated glass coverslips at a density of 10,000 cells/cm
2
. 
The neurons were treated with 1 μg/ml of α-syn PFFs with or without 1 μg/ml of 
GQDs at days in vitro (DIV) 10. At DIV 17, the mitochondria in neurons were 
stained with the MitoTracker®  Orange CMTMRos probes (Cat#: M7510; Life 
technologies). Briefly, mitochondria were stained with the 100 nM of 
MitoTracker®  Orange CMTMRos probes for 30 mins. After washing the stained 
mitochondria with a live cell imaging solution (Cat#: A1429DJ; Life technologies), 
the mitochondrial morphological characteristics were captured using a Zeiss 




the major and minor axis) were measured by ImageJ software 
(http://rsb.info.nih.gov/ij/, NIH). 
Determination of oxygen consumption rate. The Seahorse XF cell mito stress 
test kit (Cat#: 103015; Agilent) was used for measuring the oxygen consumption 
rate (OCR). Briefly, the primary cultured cortical neurons were plated onto the 24 
well culture plate at a density of 500,000 cells/well. Neurons were treated with 1 
μg/ml of α-syn PFFs with or without 1 μg/ml of GQDs at DIV 10. At DIV 17, the 
neurons were incubated in complete Seahorse assay medium at 37 
o
C for 1 hour 
after washing with warmed PBS. The assay plate was then loaded in an XF24 
analyser (XF24 EX extracellular flux analyser, Seahorse Bioscience) and the OCR 
was calculated. The OCR was measured with specific measurement protocol (1-
min mix, 1-min wait, and 2-min measurement). To assess the coupling of 
respiratory, chain, the basal respiration, and mitochondrial respiratory capacity, 
Oligomycin, carbonyl canide m-chlorophenyllhydrazone (CCCP), and rotenone 
were sequentially injected to the Seahorse assay plate. The measured OCRs were 
normalised relative to the protein concentration in each well. Data are presented as 
the percentage of change as compared with control. 
Live imaging. Primary cortical neurons were seeded onto poly-d-lysine coated 
glass bottom dish (Cat#: 150682; NuncTM) at a density 10,000 cells/ cm
2
 and 
maintained in a 7% CO2 incubator at 37 
o
C. At DIV 7, the neurons were treated 
with 1 μg/ml FITC labelled α-syn-PFFs, 1 μg/ml GQDs-biotin and streptavidin 
Qdot complex, and 100 nM LysoTracker™ Blue DND-22 (Cat#: L7525; Life 
technologies) containing live cell imaging solution for 1 hour. For time-lapse 
confocal live imaging, the temperature controlled CO2 incubation system equipped 




images were taken at the indicated intervals with 488 nm and 561 nm laser 
excitations. 
In vitro BBB permeability of GQDs. For in vitro BBB experiments, 10-pups of 
C57BL/6 mouse were used for preparing primary mouse astrocytes as previously 
described
30
. Briefly, the cerebral cortex was isolated from 1-d-old C57BL/6 mice 
and the meninges were removed. The cerebral cortex was mechanically disrupted 
by 30-ml syringe with 19-gauge needle. The isolated cells were plated onto 75 cm
2
 
T-flasks with complete DMEM culture medium. After 2 weeks, the 95% pure 
astrocytes were isolated by an astrocyte isolation kit (Cat#: 130-096-053; Miltenyl 
Biotec). The primary brain microvascular endothelial cells (BMEC) from C57BL/6 
mice were purchased from Cell Biologics as well. The purities of cultured 
astrocytes (>95%) and BMEC (>95%) were confirmed by fluorescence staining 
with cell specific marker GFAP (for astrocyte) and CD31 (for BMEC, Cat#: 
ab28364; 1:500; abcam). For the formation of an in vitro BBB, the isolated 
astrocytes were seeded at a density of 106 cells/ml onto the underside of the inserts 
(collagen-coated 0.4 μm transwell inserts; Cat#: CLS3491; Sigma-Aldrich) and 
incubated for 48 hours at 37 °C in 5% CO2 incubator. The inserts were then placed 
carefully into a 6-well plate where BMEC were plated at a density of 106 cells/ml 
on top of the inserts. The transepithelial electrical resistance (TEER) was 
determined to confirm the structural integrity of the in vitro BBB by the epithelial 
volt/ohm (TEER) meter (Cat#: 300523; EVOM2; world precision instruments) at 0, 
2, 4, 6, and 8 days after BMEC seeding. BBB impermeable 3 kDa 
dextranfluorescein (Cat#: D3306; Life technologies) were loaded inside (the blood 
side) of the in vitro BBB to confirm the integrity and calculated the ratio using 




fluorescein; Ex=555 nm / Em=580 nm for dextran rhodamine). The concentrations 
of remaining GQDs, GQDs-biotin, nano-GOs, and rGQDs were measured at 520 
nm (Ex=310 nm) using the FluoroBriteTM DMEM media (Cat#: A1896701; Life 
technologies) of inside (the blood side) and outside (the brain side) of the inserts. 
Exosome isolation. To measure the concentration of GQDs-biotin from the 
released exosome, BMEC or astrocytes were plated on 6 cm dishes and 5 μg of 
GQDs-biotin were treated for 12 hours. After 12 hours, the culture medium was 
changed, and the exosomes were isolated using an exosome isolation reagent 
(Cat#: 4478359; ThermoFisher) after 24 and 48 hours. 
Animals. All animal-based experimental procedures followed the guidelines of the 
Laboratory Animal Manual of the NIH Guide to the Care and Use of Animals. The 
procedures were approved by the Animal Care and Use Committee of Johns 
Hopkins Medical Institute. The human α-syn-A53T transgenic mice (stock no. 




In vivo BBB permeability of GQDs. For in vivo immunostaining of GQDs-biotin, 
8-week old C57BL/6 mice were i.p. injected with 2 mg/kg GQDs-biotin. The 
removed brains were fixed with 4% PFA for 6 hours. The brains were then stored 
in 30% sucrose for 48 hours for the following immunohistochemical staining. The 
biotin signals of the olfactory bulb, neocortex, midbrain and cerebellum were 
visualised using DAB staining kit. The GQDs-biotin positive signals in cells of the 
aforementioned regions were confirmed by immune-EM staining using 
GoldEnhanceTMEM Plus solution with 20-min incubation, following the 
manufacturer’s instructions. For in vivo BBB experiments, 8-week old C57BL/6 




and 14 days, the brain and blood were harvested, and the brain was homogenated 
with 1% TX-100 in PBS. The plasma was prepared by clot removed with 
centrifuging at 2,000 × g for 10 mins after the whole blood storing at RT for 30 
mins. The concentrations of GQDs-biotin were measured using QuantTag Biotin 
Kit (Cat# BDK-2000, Vector Laboratories). The ratio of brain/plasma 
concentration of GQDs-biotin was calculated against the brain/plasma ratio. 
α-syn aggregation formation assay. HEK293T cells were purchased from 
American Type Culture Collection (ATCC) and authenticated by STR analysis. 
HEK293T cells were routinely tested and found to be negative of mycoplasma 
contamination. HEK293T cells were seeded on glass coverslides and transfected 
the pCMV5 vectors with myc-tagged A53T α-syn mutant (kindly gifted by Dr. 
Thomas C. Südof), followed by treatment with PBS (pH 7.4) or GQDs (0.1 μg/ml). 
48 hours after the treatment, cells were washed three times with PBS and fixed for 
20 mins at RT in 4% PFA containing PBS. The fixed cultures were permeabilised 
for 4 mins in 0.1% Triton X-100 containing PBS. The expression of α-syn was 
monitored by immunostaining with α-syn antibody (Cat#: 610787; 1:1,000; BD 
Biosciences). The subcellular localisation of α-syn aggregates were determined by 
the confocal microscopy with serial excitations at 550 nm and 570 nm. The number 
of α-syn aggregates per field was measured using ImageJ software 
(http://rsb.info.nih.gov/ij/, NIH). 
Stereological assessments. C57BL/6 mice (8- to 10-week-old males) for 
stereological injection were purchased from the Jackson Laboratory. After 
anaesthetizing with 60 mg/kg of pentobarbital sodium solution, mice were injected 
with PBS (2 μl) or PFFs (5 μg per 2 μl) by stereotaxic instruments (cat. no. Model 




the striatum was + 2.0 mm from the midline, + 2.6 mm beneath the dura, and + 0.2 
mm relative to the bregma. As a treatment, 50 μl of GQDs (50 μg per mouse) were 
i.p. injected for 6 months on a biweekly (every two weeks) basis. After 6 months of 
GQDs injection, mice were perfused and fixed with 4% PFA containing PBS for 12 
h, followed by cryoprotection with 30% sucrose. For TH and Nissl staining, 50 μm 
coronal sections were cut using a cryostat (Bio-Rad), and every fourth section was 
used for stereological assessment. Sections were incubated with rabbit polyclonal 
anti-TH (cat. no. NB300-19, 1:1,000, Novus Biologicals) or rabbit polyclonal anti-
pS129-α-syn (cat. no. ab59264, 1:1,000, abcam) with 5% NDS, 0.1% TX-100 
containing PBS blocking solution. The sections were then incubated with 
streptavidin-conjugated HRP and biotinylated secondary antibodies (cat. no. PK-
6101, Vector Laboratories). Immune-positive signals were visualized using a DAB 
kit (cat. no. SK-4100, Vector Laboratories). To identify the Nissl substance, the 
TH-stained tissues were counterstained with thionin-containing staining solution. 
The total number of TH- and Nissl-positive neurons in the SN region was 
quantified by microscopy with Stereo Investigator software (MBF Bioscience). 
In vivo immunohistochemistry. The isolated brains were perfused and fixed with 
4% PFA containing PBS. After cryoprotection with 30% sucrose, mouse brain 
sections were incubated with anti-GFAP (cat. no. Z0334, 1:2,000, Dako) or anti-
Iba-1 (cat. no. 019-19741, 1:1,000, Wako) antibodies with blocking solution. The 
brain sections were then followed by incubation with biotin-tagged anti-rabbit 
second antibody. After incubation with ABC solution (cat. no. PK-6101, Vector 
Laboratories), brain sections were developed using a DAB peroxidase substrate kit 
(cat. no. SK-4100, Vector Laboratories). The densities of astrocytes and total 




software (http://rsb.info.nih.gov/ij/, NIH). For histopathology of major organs such 
as the liver, kidney and spleen, 8- to 10-week-old male C57BL/6 mice were i.p. 
injected with 50 μg of GQDs on a biweekly basis for 6 months. After the 6 months 
of injections, mice were perfused with 4% PFA containing PBS. The liver, kidney 
and spleen were then stained with an H&E staining kit (cat. no. H-3502, Vector 
Laboratories). 
Behaviour analyses. The cylinder test
28
 was devised to identify any asymmetry in 
forelimb use. Every contact made by a forepaw in a 20-cm-wide clear glass 
cylinder was scored by a blinded observer using video clips. No habituation of the 
mice to the testing cylinder was allowed before making the video clips. A total of 
20 to 30 wall touches were counted per animal (only contacts with fully extended 
forelimbs). The degree of impaired forelimb touches was converted to percentage 
based on the total forelimb use. The control group scored approximately 50% in 
this test. The mice were completely isolated from the test cylinder before actual 
testing. 
For the pole test
29
, test mice were allowed to adapt to the behavioural 
room for 30 min before testing. A 75 cm metal pole with a diameter of 9 mm was 
prepared with bandage gauze wrapping. To initiate the test, each mouse was placed 
7.5 cm from the top facing upwards. The scores were based on the total time taken 
to reach the bottom. The test animals were trained for two successive days before 
the actual trial, where each practice provided three different trials. No more than 60 
s was allowed for each animal. The results for the turn down, climb down and the 
total time (in seconds) were recorded. 
Clasping test
31
: For behaviour test of hA53T α-syn mice, the hindlimb 




animals were lifted by grasping their tails near the base and their hindlimb 
positions were observed for 10 secs. The clasping functional scores are rated on the 
following criteria: 1) Score 0: hindlimbs are spread outwards and away from the 
abdomen. 2) Score 1: For more than 5 secs, single hindlimb is drawn back towards 
the abdomen. 3) Score 2: For more than 5 secs, both hindlimbs are partially drawn 
back towards the abdomen. 4) Score 3: For more than 5 secs, both hindlimbs are 
completely drawn back towards the abdomen. 
Preparation of nano-GOs and rGQDs. To prepared nano-GOs, pristine GOs 
were synthesized by improved Hummer’s method according a previous literature
32
. 
Obtained GOs powder was subsequently tip-sonicated in DI water (10 mg/ml) for 3 
hours to yield nano-GOs. The reduction of GQDs was achieved by the autoclave-
based hydrothermal method at 200 
o
C for 2 hours. 
The viability assay of human neuroblastoma cell line. SH-SY5Y (ATCC®  
CRL-2266™) was purchased from ATCC and authenticated by STR analysis. Cells 
were routinely tested for mycoplasma contamination and found to be negative. SH 
SY5Y cells were plated at a density 50,000 cells/well in 48-well plate and 
incubated in 5% CO2 incubator at 37 
o
C. The viability of SH-SY5Y cells was 
quantified by alamarBlue cell viability assay kit (Cat#: DAL1025; Molecular 
Probes™), following the manufacturer’s instructions. 
Statistics. Mean ± s.d. values were determined from more than three independent 
experiments. To determine the statistical significance, P values were determined by 
Student’s t-test or ANOVA with Bonferroni correction. Prism6 software was used 
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Figure 3-S1. Schematic overview of the therapeutic effect of GQDs on the pathogenesis of 
PD. Without GQDs, pathological α-syn monomers undergo spontaneous fibrillization to 
form fibrillary aggregates, which ultimately induces loss of dopaminergic neurons, LB/LN 
like pathology and behavior deficits. On the other hand, GQDs treatment inhibits α-syn 
fibrillization and disaggregates mature fibrils to monomers and thereby prevents 
dopaminergic neuron loss, LB/LN-like pathology and behavior deficits provoked by 





Figure 3-S2. Synthesis and biotinylation of GQDs and binding assay between GQDs-biotin 
and α-syn fibrils. a, Schematic representation of synthetic procedure from carbon fibre. b, 
AFM image of synthesised GQDs. c, Fractions of GQDs with different thicknesses. d, 
Schematic representation of synthetic procedure of biotinylation on GQDs. e, FT-IR 
spectrum of GQDs (black line) and biotinylated GQDs (red line) with designated peaks and 
shifts for the functional groups. f, Schematic representation of the preparation steps for the 
binding assay between biotinylated GQDs and nanogold-streptavidin tagged α-syn fibrils. g, 
TEM images of preformed α-syn fibrils after 7 days in the presence of GQDs-biotin-





Figure 3-S3. The effect of GQDs on disaggregation of α-syn fibrils. a, The distribution of 
α-syn fibril lengths at various time points (0, 6, 12, 24, and 72 hours, n=50 fibrils at each 
time point). b, AFM images of α-syn fibrils with GQDs after various time points (0, 24, and 
48 hours) and the representative line profiles of the designated regions, marked by blue 
(GQDs) and red (α-syn fibrils) arrows at each time point.  
 
 
Figure 3-S4. The effect of GQDs on disaggregation of α-syn PFFs. a, Representative TEM 
images of fibrillized α-syn PFFs (5 mg/ml) incubated in the absence of (top) and in the 
presence of (bottom) GQDs (5 mg/ml) for 1 hour. b, The end-to-end length of α-syn PFFs 
after 1 hour of incubation. Mean ± s.d. values are 66.52 ± 34.53 and 54.49 ± 26.74 for PFFs 
and PFFs+GQDs (n=286: PFFs, n=249: PFFs + GQDs; two-tailed Student’s t-test). c, The 
amount of remaining α-syn PFFs and disaggregated α-syn PFFs assessed by BN-PAGE 
after various incubation periods. These experiments were independently repeated three 













N HSQC spectra of 
15
N-labelled α-syn monomers only (black) and after incubation with GQDs (red). The 
assigned residues designate 
15
N-labelled α-syn monomers only group. b, A full HSQC 
spectrum of 
15
N-labelled α-syn monomers incubated with GQDs. Based on the peak 
intensity of 
15
N-labelled α-syn monomers only group, the residues with no or minimal 
decrease in peak intensity (red), the residues with significant decrease in peak intensity 





Figure 3-S6. The effect of GQDs on α-syn PFFs-induced cell death and restricted neurite 
outgrowth. a, Representative TUNEL-positive neurons. DIV 10 primary cortical neurons 
were treated with α-syn PFFs (1 μg/ml) in the absence and presence of GQDs (1 μg/ml). 
TUNEL assay was performed after 7 days of incubation. b, Representative micrographs of 
neurite outgrowth and cell viability assays stained by outer cell membrane (red) and cell-
permeable viability indicator (green). c-d, Quantifications of neurite outgrowth and neuron 
viability from the stained images. Mean values of the neurite outgrowth are 100.00, 106.89, 
49.08, and 92.98 for PBS, GQDs, PFFs, and PFFs+GQDs; mean values of the cell viability 
are 100.00, 95.08, 61.43, and 89.68 for PBS, GQDs, PFFs, and PFFs+GQDs (n=6, 
biologically independent samples; two-way ANOVA with a post hoc Bonferroni test; NS, 
not significant; error bars are the standard deviation). e, Representative immunoblot 
analysis of SNAP25 and VAMP2 protein levels. 10 DIV primary cortical neurons were 
treated with α-syn PFFs (5 μg/ml) in the absence and presence of GQDs (5 μg/ml) and 
incubated for 7 days. f, The expression levels of SNAP25 were normalised to -actin level 
and quantified. Mean values are 100.00, 102.6, 69.98, and 98.68 for PBS, GQDs, PFFs, and 
PFFs+GQDs (n=4, biologically independent sample; two-way ANOVA with a post hoc 
Bonferroni test; NS, not significant; error bars are the standard deviation). g, VAMP2 were 
normalised to -actin level and quantified. Mean values are 100.00, 102.33, 75.80, and 
103.55 for PBS, GQDs, PFFs, and PFFs+GQDs (n=4, biologically independent samples; 









Figure 3-S7. The effect of GQDs on α-syn PFFs-induced mitochondrial dysfunction and 
oxidative stress. a, Representative 8-OHG immunostaining images in primary cortical 
neurons treated with α-syn PFFs (1 μg/ml) in the absence and presence of GQDs (1 μg/ml) 
and incubated for 7 days. b, Quantifications of 8-OHG content by the immunofluorescence 
levels. Mean values are 1.00, 0.66, 6.01, and 2.54 for PBS, GQDs, PFFs, and PFFs+GQDs 
(n=5, biologically independent samples; two-way ANOVA with a post hoc Bonferroni test; 
NS, not significant; error bars are the standard deviation). c, Measurements of the 
mitochondrial complex I activity after 7 days of α-syn PFFs (1 μg/ml) incubation. Mean 
values are 0.52, 0.53, 0.35, and 0.51 for PBS, GQDs, PFFs, and PFFs+GQDs (n=5, 
biologically independent samples; two-way ANOVA with a post hoc Bonferroni test; NS, 
not significant; error bars are the standard deviation). d, Representative MitoTracker 
positive micrographs. 10 DIV primary cortical neurons were treated with α-syn PFFs (1 
μg/ml) in the absence and presence of GQDs (1 μg/ml). After 7 days of incubation, 
mitochondria were labelled with MitoTracker®  Orange CMTMRos (Red). e, 
Quantifications of the length of the stained mitochondria. Mean values are 2.55, 2.49, 1.38, 
and 2.33 for PBS, GQDs, PFFs, and PFFs+GQDs (n=50, biologically independent samples; 
two-way ANOVA with a post hoc Bonferroni test; NS, not significant; error bars are the 
standard deviation). f, Aspect ratio of the stained mitochondria. Mean values are 2.22, 2.15, 
1.53, and 2.14 for PBS, GQDs, PFFs, and PFFs+GQDs (n=10, biologically independent 
samples; two-way ANOVA with a post hoc Bonferroni test; NS, not significant; error bars 
are the standard deviation). g, Representative TEM images with low and high 
magnifications after the same preparation steps. h, Microplate-based respirometry readings 
for neurons. The oxygen consumption rate was measured in an XF 24 Seahorse analyser in 
primary cortical neurons treated with α-syn PFFs (1 μg/ml) in the absence and presence of 
GQDs (1 μg/ml) for 24 hours. Mean values are 111.84, 116.36, 103.08, 107.07, 105,15, 
111,79, 94,42, 54,67, 55,42, 50.81, 139,74, 137.09, 127.98, 28.09, 32.08, and 32.68 for 
PBS group; 106.87, 107.41, 105.22, 108.21, 113.83, 107.85, 100.25, 61.22, 58.81, 60.01, 
140.25, 131.73, 128.53, 37.23, 47.80, and 37.92 for GQDs group; 91.65, 104.99, 93.36, 
90.06, 94.11, 100.81, 86.56, 47.58, 56.70, 53.91, 109.52, 112.07, 108.72, 23.60, 27.08, and 
35.31 for PFFs group; 104.20, 115.69, 109.04, 115.20, 113.70, 111.38, 106.44, 66.55, 66.09, 
65.96, 147.19, 135.62, 129.37, 37.86, 40.70, and 46.95 for PFFs+GQDs (n=4, biologically 
independent experiments). i, Quantifications of the basal respiratory rate. Mean values are 
107.84, 106.68, 90.91, and 110.78 for PBS, GQDs, PFFs, and PFFs+GQDs (n=4, 
biologically independent experiments; two-way ANOVA with a post hoc Bonferroni test; 
NS, not significant; error bars are the standard deviation). j, Quantifications of the maximal 
respiratory rates from the respirometry results. Mean values are 134.32, 133.26, 107.14, and 
139.37 for PBS, GQDs, PFFs, and PFFs+GQDs (n=4, biologically independent 
experiments; two-way ANOVA with a post hoc Bonferroni test; NS, not significant; error 





Figure 3-S8. The effect of GQDs on α-syn PFFs-induced primary neuronal toxicity and 
pathology at different treatment points of GQDs and live cell imaging. a, Neuronal 
toxicities assessed by alamarBlue and b, LDH assays. 10 DIV mouse cortical neurons were 
treated with a-syn PFFs (1 μg/ml) with 3 days pre- (n=4, Before), simultaneous (n=4, 
Simul), and 3 days post-incubation (n=4, After) of GQDs (1 μg/ml) for 7 days. Mean values 
are 100.00, 47.14, 85.27, 84.52, and 73.72 for PBS, PFFs, Before, Simul, and After of 
alamarBlue assay; 100.00, 154.64, 107.72, 109.11, and 127.62 for PBS, PFFs, Before, 
Simul, and After of LDH assay (n=4, biologically independent samples; two-way ANOVA 
with a post hoc Bonferroni test; NS, not significant; error bars are the standard deviation). c, 
Representative images of p-α-syn by dot-blot analysis and d, quantified intensities 
normalised to the PBS control. Mean values are 1.00, 14.11, 2.21, 2.14, and 4.26 for PBS, 
PFFs, Before, Simul, and After (n=4, biologically independent samples; two-way ANOVA 
with a post hoc Bonferroni test; NS, not significant; error bars are the standard deviation). e, 
Representative p-α-syn immunostaining micrographs with p-α- syn antibody at 7 days post-
incubation. f, Quantifications of p-α-syn immunofluorescence intensities normalised to the 
PBS control. Mean values are 1.00, 11.82, 2.44, 2.39, and 3.98 for PBS, PFFs, Before, 




hoc Bonferroni test; NS, not significant; error bars are the standard deviation). g, 
Representative images show that GQDs and α-syn PFFs are co-localised in the lysosome of 
primary cultured neuron with live imaging. The LysoTracker (blue), GQDs-biotin-
streptavidin Qdot complex (red), and FITC-labelled α-syn PFFs (green) were used. h, α-syn 
PFFs disaggregation process by GQDs was monitored by time-lapse fluorescence signals 
during live imaging. Experiment was independently repeated three times with duplication 






Figure 3-S9. The BBB permeability of GQDs. a, Schematic illustration of the in vitro BBB 
model. b, The confluent monolayer formations of the brain microvascular endothelial cells 
(BMEC) and astrocytes were determined by immunofluorescence staining with CD31 
(endothelial cell marker) or GFAP (astrocyte marker) antibodies, respectively. c, The 
transepithelial electrical resistance (TEER) was measured at various time points. Mean 
values are 95.95, 154.67, 299.98, 358.35, and 368.88 at 0, 2, 4, 6, and 8 d (n=6, biologically 
independent samples; one-way ANOVA with a post hoc Bonferroni test, NS, not 
significant; error bars are the standard deviation). d, The permeabilities of endothelial cell 
monolayer and astrocyte were monitored by measuring the ratio between the blood side and 
the brain side using dextran-fluorescein (3 kDa) and dextran-rhodamine (2,000 kDa) (n=4, 




biotin over time. Mean ± s.d. values are 27.86 ± 1.29, 37.71 ± 3.07, 49.65 ± 1.52, 60.78 ± 
4.28, and 93.652.55 at 2, 4, 6, 12, and 24 hours of GQDs; 21.65 ± 2.46, 31.29 ± 6.65, 43.85 
± 3.69, 57.60 ± 11.93, and 96.14 ± 2.27 at 2, 4, 6, 12, and 24 hours of GQDs-biotin (n=4, 
biologically independent samples). f, The α-syn fibril disaggregation abilities of pristine 
GQDs and GQDs-biotin monitored by dot-blot (n=3, biologically independent samples), g, 
ThT, and turbidity assays. Mean ± s.d. values are 100.00 ± 9.35, 19.04 ± 4.14, and 19.81 ± 
8.33 of α-syn fibril, α-syn fibril+GQDs, and α-syn fibril+GQDs-biotin for ThT assay; 
100.00 ± 20.35, 18.26 ± 7.60, and 18.79 ± 8.64 of α-syn fibril, α-syn fibril+GQDs, and α-
syn fibril+GQDs-biotin for turbidity assay (n=5, biologically independent samples; one-
way ANOVA with a post hoc Bonferroni test). h, Confocal laser scanning microscope 
images of primary cultured BMEC and astrocyte after 1 hour incubation with GQDs-biotin. 
GQDs-biotin are shown with Qdot™ streptavidin, whereas the lysosomes labelled by 
LysoTracker orange. i, Quantifications of the exosomal GQDs-biotin from BMEC or 
astrocytes. The amount of GQDs-biotin was measured from the isolated exosome at 24 and 
48 hours after endocytosis. Mean ± s.d. values are 11.30 ± 1.80 and 23.91 ± 4.22 for 24 h 
and 48 h of BMEC; 12.91 ± 2.46 and 25.04 ± 3.77 for 24 h and 48 h of astrocytes (n=3, 
biologically independent samples). j, Immunohistochemical analysis of i.p. injected GQDs-
biotin (2 mg/kg) by staining the olfactory bulb, neocortex, midbrain, and cerebellum with 
avidin-biotin complex method or immunogold method at 7 days after injection. The DAB 
positive stained signals were detected in GQDs-biotin-injected mice compared to vehicle-
injected control group. Immunogold positive signals were observed inside (red triangles) or 
outside of neurons (blue triangles). k, The comparison between intraperitoneal (IP; red bar) 
and intravenous (IV; blue bar) injections of GQDs-biotin. Mean ± s.d. values are 38.02 ± 
7.97 and 40.26 ± 4.10 for IP and IV at 7 d; 37.06 ± 5.02 and 34.42 ± 6.27 for IP and IV at 
14 d (n=5, biologically independent animals; two-tailed Student’s t-test; NS, not 
significant). l, The GQDs-biotin concentrations of the plasma were measured from the non-
injected control after 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 
weeks, 3 months, and 6 months (n=4, each group) after biweekly GQDs-biotin injections 
using biotin quantification kit. m, The brain (green bar) and plasma (blue bar) 
concentrations were measured from 1 hour, 7 days, and 14 days after single i.p. injection (2 
mg/kg of GQDs-biotin. Mean values are 1.46 and 0.77 for plasma and brain of 1 hour; 0.92 
and 0.40 for plasma and brain of 7 days; 0.66 and 0.26 for plasma and brain of 14 days. 
(n=4, biologically independent animals; error bars are the standard deviation). n, 3 months 
and 6 months after multiple biweekly injections. NS, not significant; Student’s ttest, error 
bars are the standard deviation. Mean values are 2.47 and 1.03 for plasma and brain of 3 
months; 1.78 and 0.71 for plasma and brain of 7 months (n=4, biologically independent 





Figure 3-S10. The effect of GQDs on α-syn PFFs-induced glial cell activation in the SN. a, 
Representative immunohistochemistry images for Iba-1 in the SN with low and high 
magnifications. Microglia in the SN of α-syn PFFs-injected hemisphere were stained with 
specific microglial marker Iba-1 (ionised calcium binding protein; specific marker of 
microglia/macrophage). b, Quantifications of Iba-1-positive microglia. Mean values are 
420.42, 445.54, 1099.80, and 544.20 for PBS/PBS, PBS/GQDs, PFFs/PBS, and 
PFFs/GQDs (n=5, biologically independent animals; two-way ANOVA with a post hoc 
Bonferroni test, error bars are the standard deviation). c, Representative 
immunohistochemistry images for GFAP in the SN with low and high magnifications. 
Astrocytes in the SN of α-syn PFFs-injected hemisphere were stained with GFAP (glial 
fibrillary acidic protein; specific marker of astrocytes) antibody. d, Quantifications of 
GFAP intensity. The relative GFAP intensities were normalised against the PBS-injected 
control group. Mean values are 1.00, 1.05, 1.46, and 1.07 for PBS/PBS, PBS/GQDs, 
PFFs/PBS, and PFFs/GQDs (n=5, biologically independent animals; two-way ANOVA 





Figure 3-S11. The effect of GQDs on pathologies and glial cell activation of hA53T α-syn 
transgenic mice. a, Schematic illustration of the observing areas of hA53T α-syn Tg model. 
As a treatment, 50 μg of GQDs or PBS were i.p. injected biweekly for 4 months. b, 
Representative p-α-syn immunostaining images in the cortex, ventral midbrain, and 
brainstem of hA53T α-syn Tg. c, Quantifications of p-α-syn immunoreactive neurons in the 
cortex (Ctx), ventral midbrain (VM), and brainstem (BS). Mean values are 100.00 and 
23.80 for PBS and GQDs of Ctx; 100.00 and 17.80 for PBS and GQDs of VM; 100.00 and 
24.60 for PBS and GQDs of BS (n=5, biologically independent animals; two-tailed 
Student’s t-test; error bars are the standard deviation). d, Representative dot-blot assay of p-
α-syn and α-syn fibrils. Experiment was independently repeated three times with similar 
results. e, Hindlimb clasping dystonic phenotypes of hA53T α-syn Tg mice were compared 
with GQDs-injected group. f, Assessment of the behavioural deficits measured by the 




α-syn Tg+PBS, and hA53T α-syn Tg+GQDs (n=5, biologically independent animals; two-
way ANOVA with a post hoc Bonferroni test, NS, not significant; error bars are the 
standard deviation). g, Assessment of the behavioural deficits measured by the pole tests. 
Mean values are 9.49, 10.05, 19.69, and 13.60 for nTg+PBS, nTg+GQDs, hA53T α-syn 
Tg+PBS, and hA53T α-syn Tg+GQDs (n=5, biologically independent animals; two-way 
ANOVA with a post hoc Bonferroni test, NS, not significant; error bars are the standard 
deviation). h, Representative immunohistochemistry images of microglia in the LC of the 
brainstem with low and high magnifications. Microglia in the brainstem of nTg or hA53T 
α-syn Tg were stained with Iba-1. i, Quantifications of Iba-1-positive microglia. Mean 
values are 371.17, 378.83, 583.67, and 405.67 for nTg/PBS, nTg/GQDs, hA53T α-syn 
Tg/PBS, and hA53T α-syn Tg/GQDs (n=6, biologically independent animals; two-way 
ANOVA with a post hoc Bonferroni test, NS, not significant; error bars are the standard 
deviation). j, Representative immunohistochemistry images of GFAP in the brainstem with 
low and high magnifications. k, Quantifications of GFAP intensity. The relative GFAP 
intensities were normalized against the PBS-injected control group. Mean values are 1.00, 
1.03, 2.17, and 1.32 for nTg/PBS, nTg/GQDs, hA53T α-syn Tg/PBS, and hA53T α-syn 
Tg/GQDs (n=6, biologically independent animals; two-way ANOVA with a post hoc 
Bonferroni test, NS, not significant; error bars are the standard deviation). l, The effect of 
GQDs on α-syn aggregate formation in HEK293 cells with hA53T α-syn overexpression. 
HEK293T cells were transfected with pCMV5-myc-A53T α-syn and the test groups were 
treated with GQDs (0.1 μg/ml). After 48 hours, cells were immunostained with α-syn 
antibodies. m, The number of immuno-positive aggregates per field was quantified and 
normalised. Mean ± s.d. values are 57.29 ± 8.45 and 14.94 ± 5.15 for PBS and GQDs (n=7, 






Figure 3-S12. Long-term in vitro and in vivo toxicity of GQDs. a, Cytotoxicity 
measurements of GQDs on DIV 10 primary cortical neurons after 7 days of incubation with 
alamarBlue and LDH assays. Mean ± s.d. values are 100.00 ± 5.65, 99.33 ± 15.08, 89.03 
±18.25, 94.10 ± 16.30, 91.95 ± 15.50, and 91.35 ± 7.31 for alamarBlue assay; 100.00 ± 
21.21, 99.02 ± 27.10, 96.14 ± 24.87, 104.31 ± 30.70, 110,13 ± 34.19, and 126.05 ± 32.53 
for LDH assays. (n=4, biologically independent samples; oneway ANOVA with a post hoc 
Bonferroni test, NS, not significant). b, Survival curves of GQDs injected mice. 50 μg of 
GQDs or vehicle were i.p. injected in C57BL/6 mice biweekly for 6 months and in vivo 
toxicity of GQDs was monitored (n=20, biologically independent animals; Log-rank test; 
NS, not significant). Statistically, there is no significant difference between GQDs and 




(H&E) staining images of the major organs. The nuclei and eosinophilic structure of the 
liver, kidney, and spleen of GQDs-injected group (n=3, biologically independent animals) 
were compared to the PBS-injected control group (n=3, biologically independent animals). 
d, Schematic illustration of the injection and sampling methods for in vivo tracking of 
GQDs-biotin. e, 50 μg of GQDs-biotin were i.p. injected in C57BL/6 mice. The 
concentrations of GQDs-biotin were measured using the brain (red) or urine (blue) of 
GQDs-biotin-injected mice at various time points (1, 3, 7, and 14 days). Mean ± s.d. values 
are 1.21 ± 0.13, 1.02 ± 0.16, 0.92 ±0.07, and 0.73 ± 0.14 at 1, 3, 7, and 14 days for Urine; 
0.89 ± 0.19, 0.79 ± 0.11, 0.43 ± 0.15, and 0.37 ± 0.20 at 1, 3, 7, and 14 days for Brain (n=4, 





Figure 3-S13. The comparative effects of nano-GOs and rGQDs on α-syn PFFs induced 
primary neuronal toxicity, disaggregation of fibrils and the BBB permeability. a, FT-IR 
spectra of pristine GQDs (black), nano-GOs (green), and reduced GQDs (rGQDs, purple) 
with designated peaks for the functional groups. b, AFM images of nano-GOs and GQDs 
with representative line profiles. c, Quantifications of the cell toxicities after 72 hours of 
incubation with 20 μg/ml of each material. Mean ± s.d. values are 100.00 ± 10.17, 102.59 ± 
11.26, 100.00 ± 9.27, 36.52 ± 6.92, 100.00 ± 10.11, and 41.66 ± 7.23 for GQDs-control, 
GQDs-72 h, nano-GOs-control, nano-GOs-72 h, rGQDs-control, and rGQDs-72 h (n=3, 
biologically independent samples; two-tailed Student’s t-test; NS, not significant). d, The 
cell toxicities monitored in SH-SY5Y cells by alarmarBlue assay at 12, 24, and 72 hours 
with various concentrations of each material (1, 10, and 20 μg/ml). Mean ± s.d. values are 
100.00 ± 5.86, 99.56 ± 5.29, 98.23 ± 4.88, and 99.98 ± 5.43 at 12 hours with PBS, 1, 10, 
and 20 μg/ml of GQDs; 100.00 ± 4.62, 87.11 ± 4.12, 82.47 ± 3.49, and 78.23 ± 3.86 at 12 
hours with PBS, 1, 10, and 20 μg/ml of nano-GOs; 100.00 ± 4.62, 80.30 ± 4.76, 72.83 ± 
3.78, and 70.46 ± 3.92 at 12 hours with PBS, 1, 10, and 20 μg/ml of rGQDs; 100.00 ± 5.08, 




GQDs; 100.00 ± 5.31, 89.91 ± 5.39, 82.98 ± 4.62, and 63.00 ± 5.48 at 24 hours with PBS, 1, 
10, and 20 μg/ml of nano-GOs; 100.00 ± 3.21, 78.96 ± 5.21, 66.12 ± 7.08, and 59.73 ± 4.56 
at 24 hours with PBS, 1, 10, and 20 μg/ml of rGQDs; 100 ± 10.17, 104.03 ± 6.78, 101.38 ± 
3.27, and 102.59 ± 11.26 at 72 hours with PBS, 1, 10, and 20 μg/ml of GQDs; 100.00 ± 
9.27, 78.34 ± 3.30, 48.53 ± 4.28, and 36.52 ± 6.92 at 72 hours with PBS, 1, 10, and 20 
μg/ml of nano-GOs; 100.00 ± 10.11, 59.37 ± 3.67, 43.04 ± 5.47, and 41.66 ± 7.23 at 72 
hours with PBS, 1, 10, and 20 μg/ml of rGQDs. (n=3, biologically independent samples). e, 
The comparative dissociation effects of GQDs, nano-GOs, and rGQDs assessed by dot blot, 
f, ThT and turbidity assays. Mean ± s.d. values are 100.00 ± 9.35, 18.86 ± 4.11, 97.86 ± 
6.57, and 95.42 ± 8.77 for α-syn fibrils, α-syn fibrils+GQDs, α-syn fibrils+nano-GOs, and 
α-syn fibrils+GQDs of ThT assay and 100.00 ± 10.46, 17.06 ± 5.99, 98.84 ± 12.86, and 
98.14 ± 12.35 for α-syn fibrils, α-syn fibrils+GQDs, α-syn fibrils+nano-GOs, and α-syn 
fibrils+GQDs of turbidity assay (n=5, biologically independent animals; one-way ANOVA 
with a post hoc Bonferroni test, NS, not significant). g, TEM images after 7 days of 
incubation (each with 5 mg/ml concentration; n=3, independent experiments). h, In vitro 
BBB permeabilities of GQDs, nano-GOs, and rGQDs using the in vitro BBB model in Fig. 
3-S9. Mean ± s.d. values are 27.9 ± 1.29, 37.71 ± 3.07, 49.65 ± 1.52, 60.78 ± 4.28, and 
93.65 ± 2.55 at 2, 4, 6, 12, 24 hours of GQDs; 1.92 ± 0.90, 2.22 ± 0.20, 9.97 ± 9.55, 11.73 ± 
11.06, and 14.06 ± 13.29 at 2, 4, 6, 12, 24 hours of nano-GOs; 23.33 ± 4.27, 27.70 ± 1.97, 
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Graphene Quantum Dots Alleviate Impaired Functions    




While the neuropathological features in Niemann-Pick type C disease (NPC) are 
fatal, development of clinically available therapeutic agent remains as a challenge 
to date. Here we report graphene quantum dots (GQDs) as a potential candidate 
against impaired functions in NPC in vivo. In addition to the previous findings that 
GQDs exhibit negligible long-term toxicity with an ability to penetrate the blood-
brain barrier (BBB), GQDs treatment decreases the accumulation of intracellular 
cholesterol through physical interactions both in vitro and in vivo. GQDs are also 
found to induce autophagy to restore compromised autophagic flux, which 
eventually reduces the atypical accumulation of autophagic vacuoles. Moreover, 
GQDs injection prevents the loss of Purkinje cells in the cerebellum with decreased 
microglial activation. The finding that GQDs alleviate impaired functions in NPC 
provides a promising potential for the treatment of NPC and related lysosomal 
storage disorders (LSDs). 
 
 
* This chapter is reproduced from: Insung Kang†, Je Min Yoo†, Donghoon Kim, Dong Jin 
Kim, Seung Eun Lee, Juhee Kim, Byung-Chul Lee, Jin Young Lee, Jae-Jun Kim, Nari Shin, 






Niemann-Pick type C disease (NPC) is a representative lysosomal storage 
disorder (LSD) characterized by heterogeneous neurovisceral symptoms including 
hepatosplenomegaly, cerebellar ataxia, and dementia at various age onsets.
1
 The 
pathogenesis of NPC is associated with the deficiency in either protein: NPC1 or 
NPC2, which harbour in the late endosomal/lysosomal (LE/LY) compartments. As 
the proteins play pivotal roles in intracellular cholesterol efflux machinery, 
defective expression of either protein leads to abnormal accumulation of 
unesterified cholesterol in the LE/LY compartments.
2-4 
While the pathological manifestations are observed throughout the body, 
neuronal dysfunction and degeneration pertaining to the cerebellum involve the 
most deleterious and ultimately fatal features in patients.
4,5
 The progression of 
neurodegeneration in NPC is known to be provoked by multiple factors. Foremost, 
the atypical cholesterol confinement disrupts cholesterol-derived cellular events 
including neurosteroidogenesis.
6
 The inclusions in the LE/LY compartments are 
recognized as damage-associated molecular patterns (DAMPs) as well, which 
eventually induce prolonged neuroinflammation indicated by activation of 
microglia/astrocytes.
7-8
 In addition, recent findings have revealed the role of NPC1 
in amphisome formation; compromised autophagic flux by defective NPC1 
expression contributes to the accumulation of autophagic vacuoles and subsequent 
cell death in NPC.
9
 Despite the urgent demand to treat neurodegenerative 
pathophysiology, no clinical drug is available for NPC patients thus far.
10
 While 
the recent outcomes with hydroxypropyl -cyclodextrin (HPCD) through phase 1-






 Namely, not only is HPCD unable to penetrate the 
blood-brain barrier (BBB), but also known to interfere with the autophagic flux to 
further complicate the relevant issues.  
In the current study, we sought to investigate the potential efficacy of 
graphene quantum dots (GQDs) against defective functions in NPC. GQDs are 
gaining growing interests in the field of nanomedicine by virtue of their notable 
properties. In particular, our group recently reported GQDs’ therapeutic role 
against α-synucleinopathy in Parkinson’s disease (PD), through which their 
negligible long-term toxicity and ability to penetrate the BBB have been validated 
in vivo.
14
 Moreover, different studies have shown graphene-based materials’ ability 
to interact with cholesterol
15,16
 and GQDs’ role in the promotion of autophagic 
flux,
17,18
 which are seemingly advantageous to manage the impaired functions in 
NPC. 
 
1.3. Results and Discussion 
GQDs were synthesized by thermo-oxidative cutting of carbon fibres in 
strong acid, and the properties were analysed with transmission electron 
microscopy (TEM), Raman spectroscopy, atomic force microscopy (AFM) and 
Fourier transform infrared spectroscopy (FT-IR) (Fig. 4-S1). To evaluate GQDs’ 
therapeutic potential in vitro, NPC patient-derived induced neural stem cells (NPC-
iNSCs) were generated according to the previous reports.
19-20
 Preliminarily, the 
relative levels of NSC-specific markers: SOX2, PAX6, Nestin, Ki67 in H9-derived 
human NSCs, wild-type NSCs (WT-NSCs) and NPC-iNSCs were measured to 





Figure 4-1. The effect of GQDs on abnormal characteristics in NPC-iNSC. a, 
Cholesterol accumulation assessed by filipin assay treated in WT iNSC and the presence 
and absence of GQDs (1 μg/ml) in NPC iNSC for 3 days. b, Aggregation of lysosomes was 
visualized by fluorescence images of LAMP1 antibody in NPC iNSC was compared with 
WT iNSC and GQDs (1 μg/ml) treated NPC iNSC. c,. Staining for Neurofilament (NF) in 
WT iNSC and NPC iNSC treated with or without GQDs (1 μg/ml) for 3days. Scale bars, 
100 μm. Data are presented as mean ± standard error of the mean (s.e.m) from three 
independent experiments. Significance levels are expressed as asterisks: ∗P < 0.05, ∗∗∗P < 





pathological hallmarks of NPC were subsequently investigated by quantifying the 
levels of intracellular cholesterol and lysosomal-associated membrane protein 1 
(LAMP1) by immunostaining with filipin and LAMP1 antibody (Fig. 4-1a,b). 
While the levels of cholesterol and LAMP1 respectively exhibited 6-fold and 2-
fold increases in NPC-iNSCs, the same analyses showed the predominant reduction 
of atypical accumulations 3 days post-GQDs treatment. It should also be noted that 
the decreased ability to differentiate in NPC-iNSCs, indicated by immature 
neuronal marker neurofilament (NF), was significantly recovered by GQDs as well 
(Fig. 4-1c). 
As hinted from the previous reports that discussed graphene-based 
materials’ specific interactions with cholesterol, we sought to elucidate the 
mechanism of cholesterol depletion by GQDs through proton nuclear magnetic 
resonance (
1
H NMR) spectroscopy at the molecular level (Fig. 4-2a and Fig. 4-
S3).
15,16
 Since cholesterol is only soluble in a few organic solvents including 
dimethyl sulfoxide (DMSO), all samples were prepared in 2% DMSO solution. 
Even in 2% DMSO, the NMR peak intensities of cholesterol were not strong 
enough to analyse. This is likely to be associated with the slow tumbling effect (i.e. 
fast relaxation of transverse magnetization) observed from molecules with high 
molecular weight, which suggests that cholesterol exists as huge aggregates in 
solution. Notably, the 
1
H NMR spectra of cholesterol exhibited distinct peak 
changes by the presence of GQDs. In particular, the peak intensities in 3.2 – 4.0 
ppm region considerably increased with a few newly appeared sharp signals (Fig. 
4-2a). The outcome suggests the compelling evidence for physical interactions 
between GQDs and cholesterol, and subsequent solubilization of cholesterol to 





Figure 4-2. Analysis of the interaction between GQDs and cholesterol in NPC-iNSC. a, 
One-dimensional 
1
H NMR spectra. NMR spectra of cholesterol only (blue), GQDs only 
(red), and cholesterol in the presence of GQDs (black). b, Magnified fluorescence images 
showing the GQDs-Biotin merge with cholesterol (Filipin) of NPC-iNSC cells. The 
concentration of GQDs-Biotin was 1 μg/ml and treated for 24 hours. Nuclei were stained 
with PI (red). Scale bar, 10 μm. c, Co-localization studies of GQDs-Biotin (green) and 
lysosome (red) using LAMP1 antibody. Scale bar, 50 μm. 
 
disaggregated insoluble α-synuclein aggregates in solution.14 To visually 
corroborate the interactions intracellularly, co-immunostaining of filipin and 
biotinylated GQDs was performed in NPC-iNSCs (Fig. 4-2b and Fig. 4-S4b). As 





Figure 4-3. The effect of GQDs on impaired autophagy in vitro. a, Fluorescence images 
of LC3 (red) of WT iNSC and NPC iNSC in the presence and absence of GQDs (1 μg/ml) 
treated for 3 days. Nuclei were stained with DAPI (blue). b, Immunoblot of LC3 antibody 
in protein samples form WT iNSC, NPC iNSC and NPC iNSC + GQDs. c, Representative 
immunoblot levels with LC3 antibody in NPC1 iNSC, NPC1 iNSC + GQDs, following 24 
h treatment with baf1. d, Filipin staining for unesterified cholesterol in NPC1 iNSC treated 
with baf1, GQDs. Scale bars, 100 μm. Data are presented as mean ± standard error of the 
mean (s.e.m) from three independent experiments. Significance levels are expressed as 
asterisks: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 via one-way ANOVA with Tukey’s multiple 
comparisons test. 
 
signals throughout the cell bodies after 24 hours of incubation. In accordance with 
Figure 1A and Figure S4A, the levels of filipin gradually decreased in time and 
showed significant reduction 3 days post-GQDs-biotin treatment. Co-
immunostaining of GQDs-biotin and LAMP1 antibody was also performed to 
verify lysosomal localization of GQDs to confirm GQDs-mediated cholesterol 




in the lysosome, which is in agreement with the GQDs-mediated α-synuclein 
disaggregation in the lysosome. Taken together, intracellular cholesterol depletion 
by GQDs mainly takes place in the lysosome, through their physical interactions.  
As mentioned, defective expression of NPC1 compromises autophagic 
pathway by disabling the fusion of autophagosome and late endosome to form 
amphisome.
9
 Therefore, the role of GQDs in the autophagic flux and subsequent 
accumulation of autophagic vacuoles was explored. The atypical accumulation of 
autophagic vacuoles can be measured by the level of microtubule-associated 
protein 1 light-chain 3 (LC3). In particular, the amount of 
phosphatidylethanolamine-conjugated LC3 (LC3-II) increases as it correlates with 
the level of the autophagosome. As shown in Fig. 4-3a and b, the levels of LC3-I 
and LC3-II were dramatically elevated in NPC-iNSCs as assessed by Western blot 
and immunohistochemistry analyses. On the other hand, the same assessments 
exhibited normal levels in the presence of GQDs. To further investigate the effect 
of GQDs on LC3-II accumulation and autophagic flux, bafilomycin A1 (Baf A1) 
was treated to block autophagic degradation (Fig. 4-3c). Although Baf A1 
treatment aggravates LC3-II accumulation by inhibiting clearance, it does not 
promote the synthesis of the autophagosome. Surprisingly, co-treatment of GQDs 
and Baf A1 caused significant increases in LC3-II accumulation. This indicates 
GQDs’ robust induction of autophagy, which seems to play the pivotal role in the 
clearance/maturation of LC3-II in NPC-iNSCs. In addition, GQDs and Baf A1 co-
treatment complicated intracellular cholesterol accumulation; GQDs-mediated 
autophagy induction is strongly associated with GQDs-mediated cholesterol 
clearance as well (Fig. 4-3d). 





Figure 4-4. The effect of GQDs on NPC1 pathologies in vivo. a, Schematic 
representation of injection of GQDs (50 μg/ml) for intraperitoneal injection in NPC1 
mutant mice. GQDs were injected weekly for 6 weeks. b, Assessments of the behavioral 
deficits measured by Rota-rod test. Mean values are ~ for NPC1 and NPC1+GQDs (n=7) c, 
Representative calbindin (CBD) immunostaining purkinje cells co-stained with filipin. 
Quantification of filipin intensities in CBD area normalized to NPC1. Mean values are 1.00 
and 0.19 for NPC1 and NPC1+GQDs. Scale bar 10 μm. d, Immunoblot analysis of LC3 in 
the cerebellum tissues of WT, NPC1 and NPC+GQDs. LC3-II level was analyzed and 
quantified by normalizing to WT. Mean values are 1.88, 10.80 and 5.49 for WT, NPC1 and 
NPC1+GQDs. e, Representative immunohistochemistry image of the cerebella labeled with 
anti-CBD for purkinje cells of NPC1 and NPC1+GQDs. Nuclei were stained with PI. f, 
Purkinje cells were labeled with anti-CBD in the anterior and posterior of NPC1 and 
NPC1+GQDs cerebellum. Nuclei were counterstained with DAPI. Quantification of 
purkinje cells were counted divided by the length of the cerebella lobe. Data are presented 
as mean ± standard error of the mean (s.e.m) from three independent experiments. 
Significance levels are expressed as asterisks: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 via one-





vivo, GQDs (2 mg/kg; 50 g) were administered into 2-week old NPC1 knockout 
mice weekly via intraperitoneal (i.p.) injection (Fig. 4-4a). Prior to any assessments, 
the BBB permeability of GQDs was re-evaluated (Fig. 4-S5). As it has already 
thoroughly verified from the previous report, we focused on: 1) In vitro 
permeability to ensure the reproducibility and 2) In vivo cerebellar localization of 
GQDs. As expected, GQDs exhibited 100% in vitro permeability after 24 hours and 
considerable amount of GQDs-biotin was found in the cerebellum without any 
appreciable toxicity. From 4 to 6 weeks post-GQDs injection, the rota-rod tests 
were carried out to monitor the changes in NPC-provoked motor deficits (Fig. 4b). 
While NPC1 mice showed significantly aggravating motor dysfunctions in time, 
GQDs-treated mice displayed respectably improved latency to fall. 
At 6 weeks post-GQDs injection, mice were sacrificed to analyze 
biochemical alterations of the pathological features in the cerebellum. As the loss 
Purkinje cells is the most striking and detrimental histological change in NPC1 
mice, the atypical cholesterol accumulation in Purkinje cells was explored by 
immunohistochemical analysis (Fig. 4-4c). While considerable amount of 
cholesterol accumulation was detected in Purkinje cells of NPC1 mice, GQDs 
injection markedly prevented the abnormal accumulation. The accumulation of 
LC3-II autophagic vacuoles was also measured by Western blot analysis, showing 
predominant reduction by GQDs (Fig. 4-4d). Furthermore, GQDs’ protective effect 
of on the loss of Purkinje cells was monitored by Calbindin-D 28K (CBD) staining 
in the cerebellum (Fig. 4-4e,f).
21
 Remarkably, the Purkinje cells in GQDs-
administered NPC1 mice were significantly protected against NPC1-induced loss 
over the entire cerebellum. It should be also noted that GQDs-injected NPC1 mice 




immunostaining with Iba1 antibody (Fig. 4-S6). This indicates only negligible 
involvement of inflammatory response by the presence of GQDs, which is likely 
associated with the rescue of Purkinje cells.  
 
1.4. Conclusion 
In this study, we investigated the potential role of GQDs against the 
impaired functions in NPC. In addition to the previous finding that revealed GQDs’ 
negligible long-term toxicity and ability to penetrate the BBB in vivo, GQDs were 
found to deplete intracellular cholesterol and promote autophagic flux. As GQDs’ 
neuroprotective effects against α-synucleinopathy in Parkinson’s disease (PD) have 
been validated as well, their therapeutic potential against other types of LSDs 
including Gaucher’s disease would also be noteworthy as the disease manifests the 
pathological features of both NPC and PD. In any case, we expect GQDs-based 
drugs will open new venues in clinical drug discovery against neurodegenerative 
diseases in the near future.  
 
1.5. Experimental  
Synthesis of GQDs. GQDs were synthesized by thermo-oxidatively cut carbon 
fibres (0.9 g, Carbon Make) in 400 ml 3:1 sulphuric acid and nitric acid (Samchun 
Chemical) at 80 
o
C for 1 day. The solution was dialyzed in DI water to remove acid 
and filtered with 20 μm membrane filter (Cat#: 6809-5002; Whatman-Anodisc 47; 
GE Healthcare). The final product in powder form was obtained after subsequent 
rotary evaporation and freeze drying procedures.  




GQDs solution was dropped onto a TEM grid and analysed with a high-resolution 
TEM (HR-TEM, JEM-3010, JEOL Ltd.). For Raman spectrum, 10 mg GQDs 
powder was prepared on a silicon substrate and measured with an Ar laser (514 
nm)-based Raman spectrometer (RENISHAW). For AFM imaging, 5 μl (10 μg/ml) 
GQDs solution was dropped onto a silicon substrate. The sample was analysed in 
non-contact mode with an XE-100 AFM (Park Systems). XE data acquisition 
program was to acquire the final image (XEP 1.8.0). For biotinylation, 10 ml 
GQDs solution (5 mg/ml) was prepared in EDC conjugation buffer (pH 4.7). After 
gentle vortex, 12.5 mg EDC reagent (N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride, Sigma-Aldrich) was added and stirred for 1 hour. 
After replacing the carboxyl groups with EDC reagent, 25 mg of amine-PEG3-
Biotin (EZ-Link, Thermo Scientific) was added and vigorously stirred for 1 day. 
The solution was dialysed and freeze-dried to yield the final GQD-biotin in powder 
form.  
Generation of patient specific iNSCs and differentiation. iNSCs were generated 
from wild type human dermal fibroblasts (hDF) (GM5659; Coriell Institute for 
Medical research, Camden, NJ) and NPC patient-derived hDFs (GM03123; Coriell 
Institute for Medical research, Camden, NJ) according to the previous report20. In 
short, retroviral pMX-SOX2 and pMX-HMGA2 were transfected into 293 FT cells 
along with VSV-G and gag/pol plasmids using Fugene 6 transfection reagent 
(Roche, Indianapolis, IN, USA). The supernatants were collected at 48 and 72 
hours post-transfection and used to infect hDFs with 5 μg/ml polybrene (Sigma-
Aldrich, Sigma, Ronkonkoma, NY, USA). After expansion of the infected cells, 
the medium was changed to the NSC maintenance medium (ReNcell NSC 
maintenance media; Millipore) with bFGF (Sigma) and EGF (Sigma) for neural 




neurosphere culture condition. For expansion, the cells were cultured as attached 
cells on PLO/FN-coated dishes. And for random differentiation, coverslips were 
coated with PlO/FN in 24-well plate and 5,000 cells of iNSCs were seeded and 
medium (Gibco BRL) with Gmax (Gibco) were added and cultured for 2 weeks. 
Immunocytochemistry. Cells cultured in 24-well plate were washed with phosphate 
buffer saline (PBS; Gibco) and fixed with 4% paraformaldehyde (PFA) for 5 
minutes at room temperature. To permeabilize the cell membrane and blocking 
stage, fixed cells were exposed to 0.5% Triton X-100 for 15 minutes and incubated 
with blocking solution containing 5% normal goat serum (NGS; zymed, San 
Francisco, CA, USA) for 1 hour at room temperature. Primary antibodies were 
used according to the manufacturer’s recommended dilution, and cells exposed to 
primary antibody were incubated overnight at 4 
o
C. For secondary antibodies, 
Alexa 488- or Alexa 594-labeled antibodies (Molecular Probes, OR, USA) was 
used and incubated at 1 hour room temperature. 4’,6-diamidino-2phenylindole 
(DAPI;Sigma) was used for nuclei staining. Images were captured on a confocal 
microscope (Nikon, Eclipse TE200, Japan). 
NMR Measurement. All NMR spectra were recorded on Bruker Biospin Avance 
700 MHz NMR spectrometer (1H frequency of 700.4 MHz) equipped with a 
cryogenic probe (Avance III, Bruker Biospin, Switzerland) at 37 
o
C. A standard 
pulse sequence with excitation sculpting (zgesgp from Bruker Topspin using the 
standard parameter set) was employed as this pulse sequence allows better 
suppression of the water signal with the excellent flat baseline through the selective 
excitation of H2O during spin-echo and the use of purge gradients. Cholesterol of 
0.05 mg/ml in 2% dimethylsulfoxide-d6 (final concentration) and GQDs of 0.5 
mg/ml were used for NMR measurements. 




poly-d-lysine-coated coverslip (10,000 cells/cm
2
). The cytotoxicity assays (LDH 
cytotoxicity assay kit, Pierce; TUNEL assay kit, Roche) were performed with 
different concentrations of GQDs in 10 DIV cortical neurons for a week.  
In vitro and in vivo BBB permeability. The procedures for in vitro and in vivo 
BBB permeability studies were reproduced from the previous report14. Briefly for 
in vitro permeability test, glial cells were harvested from 1-d-old C57BL/6 mice 
and seeded (100,000 cells/ml) under a transwell insert (Sigma-Aldrich) and 
incubated in a 5% CO2 incubator for 2 days. Separately harvested brain 
microvascular endothelial cells (BMECs) were then plated (100,000 cells/ml) on 
top of the insert. The concentrations of GQDs and GQDs-biotin were measured 
with the FluoroBriteTM DMEM media inside (BMECs) and outside (glial cells) of 
the insert. For in vivo permeability, GQDs-biotin was i.p. injected in 8-week old 
C57BL/6 mice. After fixing the brain with 4% PFA for 6 hours, it was stored in 
30% sucrose for 2 days. The DAB-based biotin signals were visualised with a DAB 
staining kit and the signals in the cerebellum and brainstem were confirmed with 
GoldEnhance
TM
EM Plus solution for immune-EM staining.  
Animal model. A breeding pair of heterozygous Balb/c NPC+/- mice was 
purchased from Jackson Laboratories (Bar Harbor, MA). Wild-type control (WT; 
NPC+/+) and NPC1-knockout (NPC1; NPC-/-) mice were generated by breeding, 
and genotyping was carried out as previously described
22
. All experiments were 
approved and followed by regulation of the Institute of Laboratory Animals 
Resources (SNU IACUC Approval No: SNU-170816-2, Title of proposal: The 
efficacy of graphene quantum dots (GQDs) against NPC mouse; Institutional 
Animal Care and Use Committee, Seoul National University, Korea). All animals 
were maintained by an authorized animal facility under strict management. 




(50 μg per mouse) were i.p. injected for 6 weeks on a weekly basis. At 8 weeks of 
age, the mice were sacrificed and the brains were sampled for immunoblotting or 
immunohistochemistry. 
Behaviour analyses. The rotarod treadmill (7650 Accelerating model, Ugo Basile 
Biological Research Apparatus, Comerio, Italy) was used to coordinate the motor 
function ability. The mice were trained for 2 weeks prior to having their motor 
function tested from 6 to 8 weeks of age, tested once per week. The rotatod speed 
was set at 10 rpm and a maximum duration of 180 seconds. Representative records 
of the subjects were adopted as the mean performance time form 4 attempts
23
. 
In vivo filipin staining and immunohistochemistry. The isolated brains were 
perfused with 0.1 M PBS (pH 7.4) followed by 4% paraformaldehyde in 0.1 M 
PBS. Isolated brains were soaked in 4% paraformaldehyde in 0.1 M PBS overnight 
for post-fixation and cryo-protected with 30% sucrose. The brain tissues were 
transferred to a mold filled with an infiltration mixture (OCT compound; Sakura 
Finetek, Tokyo, Japan) and were maintained at 70 
o
C overnight until they were 
cryosectioned at 20 µm thick on a cryostat (CM 3050, Leica, Wetzlar, Germany). 
The sections were stained with filipin as previously described to compare the levels 
of accumulated cholesterol
22
. For the immunohistochemistry analysis, mouse brain 
sections were incubated with anti-calbindin (Abcam, Cambridge, MA) antibodies 
with blocking solution. Followed by being extensively washed with PBS and 
incubated with anti-rabbit secondary antibody conjugated with Alexa Fluor 488 
(Molecular Probes, Eugene, OR, USA) for 1 h. Hoechst 33238 (1 µg/ml, Sigma-
Aldrich) staining was used to visualize the cell nuclei. The densities of purkinje 
cells and total number were measured in the cerebella by ImageJ software 
(http://rsb.info.nih.gov/ij/, NIH).  




cerebella were separated from the whole brain. With lysis buffer (Pro-PREP, Inton 
Biotechnology, Korea), the cerebellum was homogenized. DC assay kit (Bio-Rad, 
Berkeley, USA) was used for quantification of the protein concentration. Equal 
amount of protein (20 µg) were injected in the wells of 10-15% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes. After blocking the membranes with 3% bovine serum in 
a Tris-buffered saline with Tween (TBST: 20 mM Tris-HCl [pH 7.6], 137 mM 
NaCl, 1% Tween 20) and incubated with primary antibody (LC3, Novus). Proteins 
were detected by secondary antibody according to the manufacturer’s 
specifications [horseradish peroxidase (HRP)-conjugated antibody (1:2000; 
Invitrogen, Carlsbad, USA; G21234)] followed with addition of enhanced 
chemiluminescence (ECL) detection kit (Amersham Pharmacia Bioteck, 
Amersham, UK). The relative band intensities were determined by ImageJ software 
(http://rsb.info.nih.gov/ij/, NIH). 
Quantification and Statistical Analysis. Mean ± SD values were shown for more 
than three independent experiments. Through Graphic Pad Prism (v5.0, GraphPad), 
statistical analysis of the significance was calculated using with unpaired Student’s 
t-test and one-way ANOVA followed by Bonferroni post hoc analysis. 
Data Availability. There is no data relevant to accession codes or unique 
identifiers non-publicly available. The data that support the plots within this paper 





1.6. Supplementary Information 
 
Figure 4-S1. Characterisation of GQDs. a, Schematic illustration of the GQDs synthesis 
from carbon fibres. b, Representative TEM imaging and the fractional analysis of the 
synthesised GQDs. c, Representative Raman spectrum of GQDs with designated D and G 
bands. d, Representative AFM imaging and respective the fractional analysis of the 
synthesised GQDs. e, FT-IR spectra of pristine (black) and biotinylated (red) GQDs with 





Figure 4-S2. Direct conversion of NPC1 patient derived fibroblasts to neural stem 
cells. a, Schematic illustration of the process of direct conversion. b, Immunocytochemistry 
analysis of neural stem cell specific marker proteins labeled with anti-nestein, Sox2, Pax6, 




Figure 4-S3. Extended 
1
H NMR spectra. Each line represents cholesterol only (blue), 





Figure 4-S4. The time-dependent effect of GQDs on cholesterol accumulation in NPC-
iNSC and the effect of GQDs-biotin. a, GQDs were treated in NPC1 iNSC for 3 days and 
unesterified cholesterol was stained with filipin each day. Nuclei were counterstained with 
DAPI. Scale bars, 100 μm. Data are presented as mean ± standard error of the mean (s.e.m) 
from three independent experiments. Significance levels are expressed as asterisks: ∗∗P < 
0.01, ∗∗∗P < 0.001 via one-way ANOVA with Tukey’s multiple comparisons test. b, 
Cholesterol accumulation is ameliorated by GQDs-biotin. GQDs-biotin was treated in 
NPC-iNSC for 3 days and stained with filipin to analysis unesterified cholesterol. Nuclei 
were counterstained with DAPI. Scale bars, 100 μm. Significance levels are expressed as 





Figure 4-S5. Cytotoxicity, survival rate, in vitro and in vivo permeability of GQDs. a, 
LDH and b, TUNEL assays with varying GQDs concentrations for cytotoxicity studies. c, 
The mice survival rate with GQDs-injected mice for long-term in vivo toxicity analysis. d, 
Schematic illustration of the in vitro BBB study model and the permeability analysed with 
GQDs-biotin. e, DAB staining-based in vivo BBB permeability study in the cerebellum and 
brainstem with i.p. injected GQDs-biotin (2 mg/kg) mice. The red arrows point the DAB-




Figure 4-S6. Inhibited microgliosis in GQDs treated NPC1 mutant mice. Iba-1 
immunostaining and its density and count show GQDs administration could inhibit 
microgliosis in the NPC1 cerebellum. Scale bars, 100 μm. Data are presented as mean ± 
standard error of the mean (s.e.m) from three independent experiments. Significance levels 
are expressed as asterisks: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 via one-way ANOVA with 
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그래핀은 2004년 맨체스터 대학의 과학자들에 의해 처음으로 
실험적으로 발견된 이후부터 전례 없이 뛰어난 다양한 특성들로 많은 
과학자들의 이목을 끌었다. 실질적으로 ‘그래핀’이라는 용어는 흑연을 1층으로 
박리시킨 원자 한 층의 필름을 의미하며, 초기에는 이 필름을 활용해 인듐 주석 
산화물 박막을 대체할 투명 유연 디스플레이 소재로서의 가능성이 주목받았다. 
최근에는 이러한 가능성을 넘어 수용액상에 녹을 수 있는 형태의 그래핀 기반 
물질들이 지닌 다양한 생물학적, 나노의학적 분야에 적합한 특성들이 보고되며 
또 다른 주목을 받고 있다. 특히 최근 이러한 연구분야들에서 신소재를 활용한 
새로운 응용연구들이 각광받고 있으며, 우리는 다양한 시도들을 통해 몇 가지 
선구적인 결과들을 얻어낼 수 있었다. 따라서 본 논문에서는 그동안 수행한 
몇가지 연구들을 취합하여 그래핀 및 그래핀 기반 나노물질들이 인체 보건 및 
퇴행성 뇌질환 치료에 어떠한 영향을 끼치는지에 대해 보고한다.  
제1장에서는 그래핀 기반 나노물질들에 대해 생물학 및 의과학 분야 
적용 사례들과 이에 필요한 합성법 및 최근 보고된 몇 가지 독성연구에 대해 
간략히 소개한다. 
제2장에서는 CVD 그래핀 필름을 활용한 산업폐수처리 실험에 대해 
소개한다. 페놀과 페놀 기반 유기분자들은 산업폐수에 대량 포함되어 있으며 




페놀 분해 방법은 페놀을 완전히 분해시킬 수 있다는 장점은 있으나 
기초설비비용과 처리비용이 높은 편이며 처리 과정에서 발생하는 추가적인 
촉매 산물 제거 과정 및 산성조건 설정 등 부수적인 환경문제를 야기한다. 본 
연구에서는 재활용 가능한 CVD 그래핀 필름을 활용해 페놀을 분해시킬 수 
있는 활성산소를 생성하고 향후 추가적으로 개선이 가능한 새로운 환경친화적 
촉매로의 적용 가능성을 보여준다. 
제3장에서는 그래핀 양자점의 파킨슨병 치료제 개발로서의 가능성을 
소개한다. 파킨슨병의 발병과정은 그 원인이 명확히 밝혀지지는 않았으나 
알파시뉴클레인이라는 신경 단백질의 응집이 매우 중요하다고 알려져 있다. 
다양한 실험을 통해 그래핀 양자점이 알파시뉴클레인의 초기 응집을 억제할 
뿐만 아니라 이미 형성된 응집체를 풀어주고, 주변 신경세포들로의 전이를 
억제할 수 있다는 사실을 보여준다. 또한 혈뇌장벽 투과를 통해 중뇌에 있는 
도파민 작동성 신경세포의 사멸을 막아줄 수 있다는 결과들을 통해 단순히 
증상의 완화만을 목적으로 하는 기존의 약물들과는 달리 질병의 근본적 치료가 
가능한 임상 약물로서의 가능성을 보여준다.  
마지막으로 제4장에서는 그래핀 양자점을 또 다른 퇴행성 뇌질환 중 
하나인 니만피크C형에 대한 치료제로서의 가능성을 보여준다. 이 실험을 통해 
그래핀 양자점이 세포 내 비정상적 콜레스테롤 축적 및 손상된 자가포식현상에 
도움을 줄 수 있다는 결과를 소개하고자 한다.  
주요어: 그래핀, 그래핀 양자점, 환경촉매, 의과학적 적용, 나노의학, 퇴행성 
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